

**International Journal of Molecular Science:**  
Special Issue „Cytokine-Induced Killer (CIK) Cells“

Deadline for manuscript submissions: 31 March 2017

Special Issue Editor: Prof. Dr. Info Schmidt-Wolf

For more information: [http://www.mdpi.com/journal/ijms/special\\_issues/CIK](http://www.mdpi.com/journal/ijms/special_issues/CIK)

### ZEITSCHRIFTENARTIKEL

1. **Schmidt-Wolf I**, Brandhorst D, Hertenstein C, Wetter O. Results with a modified human myeloma stem cell assay. *Klin Wochenschr* 61:1101-1103 (1983)  
IF: 0
2. **Schmidt-Wolf IGH**, Aihara M, Negrin RS, Blume KG, Chao NJ. Lymphokine-activated killer cell activity after cryopreservation. *J Immunol Meth* 125:185-189 (1989)  
IF: 1.8
3. **Schmidt-Wolf I**, Fischer J. Einfluss eines Aufenthaltes im Nordseeklima auf die Lymphozytensubpopulationen im peripheren Blut bei Patienten mit exogen allergischem Asthma bronchiale und chronischer Bronchitis. *Pneumologie* 44, 241-242 (1990)  
IF: 0
4. Fischer J, **Schmidt-Wolf I**, Raschke F. Einfluss eines mehrwoechigen Aufenthaltes im Nordseeklima auf die Lymphozytensubpopulationen bei Patienten mit Neurodermitis und Atemwegserkrankungen. *Z Phys Med Baln Med Klim* 19:320-324 (1990)  
IF:0
5. Negrin RS, Kiem HP, **Schmidt-Wolf IGH**, Blume KG, Cleary ML. Use of the polymerase chain reaction to monitor the effectiveness of tumor cell purging with antibodies and complement. *Blood* 77(3):654 -660 (1991)  
IF: 10.5
6. Aihara M, Aihara Y, Schmidt -Wolf G, **Schmidt-Wolf IGH**, Sikic BI, Blume KG, Chao NJ. A combined approach for purging multidrug resistant leukemic cell lines in bone marrow, using a monoclonal antibody and chemotherapy. *Blood* 77(9):2079 -2084 (1991)  
IF: 10.5
7. **Schmidt-Wolf IGH**, Negrin RS, Kiem HP, Blume KG, Weissman IL. Use of a SCID mouse / human lymphoma model to evaluate cytokine-induced killer cells with potent anti-tumor cell activity. *J Exp Med* 174(1):139-149 (1991; cited in *Science* 259:1463 (1993))  
IF: 12.5
8. **Schmidt-Wolf IGH**, Aihara M, Negrin RS, Blume KG, Chao NJ. In vitro and in vivo activity of murine lymphokine-activated killer cells after cryopreservation. *Transfusion* 32(1):42-45 (1992)  
IF: 2.4

9. Schlegel PG, **Schmidt-Wolf G**, **Schmidt-Wolf IGH**, Kwak LW, Chao NJ. Lymphokine-activated killer cell activity against autologous lymphoma cells following bone marrow transplantation. *Cancer Research, Therapy and Control* Vol.3:145 -152 (1993)  
IF: 0.5
10. **Schmidt-Wolf IGH**, Lefterova P, Mehta BA, Fernandez LP, Huhn D, Blume KG, Weissman IL, Negrin RS. Phenotypic characterization and identification of effector cells involved in tumor recognition of cytokine-induced killer cells. *Experimental Hematology* 21:1673-1679 (1993)  
IF: 2.3
11. **Schmidt-Wolf IGH**, Dejbakhsh-Jones S, Ginzton N, Greenberg P, Strober S. T cell subsets and suppressor cells in human bone marrow. *Blood*, 80(12):3242 -3250 (1992)  
IF: 10.5
12. **Schmidt-Wolf IGH**, Liang O, Dejbakhsh-Jones S, Wang H, Cheng L, Holm B, Bell R, Strober S. Homogeneous antigen receptor beta chain genes in cloned CD4+ - CD8+ - alpha, beta+ T suppressor cells. *J Immunol.* 151:5348-5353 (1993)  
IF: 4.9
13. **Schmidt-Wolf IGH**, Schwerdtfeger R, Schwella N, Gallardo J, Schmid H, Huhn D, Siegert W. Diffuse pulmonary alveolar hemorrhage after allogeneic bone marrow transplantation. *Ann Hematol*, 67:139-141 (1993)  
IF: 2.6
14. Schwella N, Schwerdtfeger R, **Schmidt-Wolf I**, Schmid H, Siegert W. Pneumococcal arthritis after allogeneic bone marrow transplantation. *Bone Marrow Transplantation* 12:165-166 (1993)  
IF: 3.6
15. Lefterova P, Negrin R, Neubauer A, Huhn D, Blume K, **Schmidt-Wolf I**. Efficient generation and characterization of tumor cell subclones with different adhesion pathways involved in cell lysis. *Haematologica*, 78(6), 353 -358 (1993)  
IF: 5.8
16. Schwella N, Koenig V, Schwerdtfeger R, **Schmidt-Wolf I**, Schmid H, Riess H, Siegert W. Ondansetron for efficient emesis control during total body irradiation. *Bone Marrow Transplantation* 13, 169-171 (1994)  
IF: 3.6
17. **Schmidt-Wolf IGH**, Lefterova P, Johnston V, Neubauer A, Huhn D, Negrin R, Blume KG. Propagation of T cells with NK cell marker. *Br J Haematol* 87, 453-458 (1994)  
IF: 5.0
18. Schwella N, Schwerdtfeger R, Koenig V, Blasczyk R, Schmid H, Schmidt -Wolf I, Henze G, Siegert W. Allogeneic bone marrow transplantation for recurrence of leukemia after autologous bone marrow transplantation. *Transplantation* 57, 1263-1265 (1994)  
IF: 3.8
19. **Schmidt-Wolf IGH**, Neubauer A, Finke S, Csipai M, Wittig B, Huhn D. Interleukin-7 gene therapy for patients with metastatic colon cancer, renal cell cancer, malignant melanoma or lymphoma. *Human Gene Ther* 5(9), 1161-1168 and 1197 (1994)  
IF: 3.8
20. **Schmidt-Wolf G**, **Schmidt-Wolf I**. Human cancer and gene therapy. *Ann Hematol* 69(6), 273-279 (1994)  
IF: 2.6
21. Scheffold C, Brandt K, Johnston V, Lefterova P, Huhn D, Neubauer A, Negrin RS, **Schmidt-Wolf IGH**. Potential of autologous cytokine induced killer cells for bone marrow purging in patients with chronic myeloid leukemia. *Bone Marrow Transplantation* 15, 33-39 (1995)

- IF: 3.6
22. Schmidt -Wolf G, **Schmidt-Wolf** IGH. Cytokines and gene therapy. *Immunol Today* 16(4), 173-175 (1995)  
IF: 12.9
  23. **Schmidt-Wolf** GD, **Schmidt-Wolf** IGH. Bone marrow and clinical gene therapy. *J Hematother* 4, 551-561 (1995)  
IF: 2.5
  24. **Schmidt-Wolf** G, **Schmidt-Wolf** IGH. Cytokines and clinical gene therapy. *Europ J Immunol* 25(4), 1137-1140 (1995)  
IF: 4.0
  25. Csipai M, Lefterova P, Finke S, Johnston V, Scheffold C, Huhn D, **Schmidt-Wolf** IGH. Effects of interleukin-7 on proliferation of tumor cells. *Cancer Research, Therapy and Control* (5), 11-16 (1996)  
IF: 0.5
  26. **Schmidt-Wolf** IGH, Lefterova P, Johnston V, Scheffold C, Csipai M, Mehta B, Tsuruo T, Huhn D, Negrin RS. Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells. *Cell Immunol* 169, 85-90 (1996)  
IF: 1.9
  27. **Schmidt-Wolf** IGH, Grimm B, Lefterova P, Johnston V, Scheffold C, Huhn D, Serke S. Propagation of large numbers of cells of a human mixed-lineage T-lymphoid/myeloid. *Br J Haematol* 90, 512-517 (1995)  
IF: 5.0
  28. Mehta BA, **Schmidt-Wolf** IGH, Weissman IL, Negrin RS. Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3+CD56+ killer cells. *Blood* 86(9), 3493-3499 (1995)  
IF: 10.5
  29. Finke S, Trojaneck B, Moeller P, Schadendorf D, Neubauer A, Huhn D, **Schmidt-Wolf** IGH. Increase of cytotoxic sensitivity of primary human melanoma cells transfected with the interleukin-7 gene. *Cancer Gene Ther* 4(4), 260-268 (1997)  
IF: 2.4
  30. Lefterova P, **Schmidt-Wolf** IGH. Coexpression of lymphoid and myeloid markers on cell surfaces. *Leukemia and Lymphoma* 26, 27-33 (1997)  
IF: 2.9
  31. **Schmidt-Wolf** GD, Negrin RS, **Schmidt-Wolf** IGH. Activated T cells and cytokine-induced CD3+CD56+ killer cells. *Annals Hematol* 74, 51-56 (1997)  
IF: 2.6
  32. Schriever F, Korinth D, Salahi A, Lefterova P, **Schmidt-Wolf** IGH, Behr SI. Human T lymphocytes bind to germinal centers of human tonsils via integrin alpha4/VCAM-1 and FA-1alpha/ICAM-1 and -2. *Europ J Immunol* 27, 35-39 (1997)  
IF: 4.0
  33. Ebert O, Finke S, Salahi A, Herrmann M, Trojaneck B, Lefterova P, Wagner E, Kircheis R, Neubauer A, Huhn D, Schriever F, Wittig B, **Schmidt-Wolf** IGH. Lymphocyte apoptosis: Induction by gene transfer techniques. *Gene Therapy* 4, 296-302 (1997)  
IF: 3.1
  34. Finke S, Trojaneck B, Lefterova P, Csipai M, Wagner E, Kircheis R, Neubauer A, Huhn D, Wittig B, **Schmidt-Wolf** IGH. Increase of proliferation rate and enhancement of antitumor cytotoxicity of expanded human CD3+CD56+ immunologic effector cells by receptor-mediated transfection with the interleukin-7 gene. *Gene Ther* 5, 31-39 (1998)  
IF: 3.1

35. Mueller M, Scheffold C, Lefterova P, Huhn D, Neubauer A, **Schmidt-Wolf I**. Potential of autologous immunologic effector cells for the prediction of progression of disease of patients with chronic myeloid leukemia. *Leukemia and Lymphoma* 31, 335-341 (1998)  
IF: 2.9
36. Mann B, Gratchev A, Riede E, **Schmidt-Wolf I**, Trojanec B, Moyer MP, Hanski C, Buhr HJ. Beta-catenin overexpression in metastasized colorectal carcinomas - an important mechanism during the progression of the disease? *Langenbecks Arch Chir I, Forumsband 1998*, 303-306 (1998)  
IF: 2.2
37. **Schmidt-Wolf GD, Schmidt-Wolf IGH**. Cancer and gene therapy. *Ann Hematol* 73, 207-218 (1996)  
IF: 2.6
38. Zoll B, Lefterova P, Finke S, Trojanec B, Ebert O, Micka B, Roigk K, Fehlinger M, **Schmidt-Wolf GD**, Huhn D, **Schmidt-Wolf IGH**. Generation of cytokine-induced killer (CIK) cells using exogenous interleukin-2 (IL-2), -7 (IL-7) or -12 (IL-12). *Cancer Immunol Immunother* 47(4), 221-226 (1998)  
IF: 3.9
39. Glasmacher A, Molitor E, Hahn C, Bomba K, Ewig S, Leutner C, Wardelmann E, **Schmidt-Wolf IGH**, Mezger J, Marklein G, Sauerbruch T. Antifungal prophylaxis with itraconazole in neutropenic patients with acute leukaemia. *Leukemia* 12, 1338-1343 (1998)  
IF: 10.4
40. Flieger D, Spengler U, Beier I, Kleinschmidt R, Hoff A, Varvenne M, Sauerbruch T, **Schmidt-Wolf I**. Enhancement of ADCC by combination of cytokines. *Hybridoma* 18(1), 63-68 (1999)  
IF: 0.3
41. Mann B, Gratchev A, Böhm C, Hanski ML, Foss HD, Demel G, Trojanec B, **Schmidt-Wolf I**, Stein H, Riecken EO, Buhr HJ, Hanski C. FasL is more frequently expressed in liver metastases than in matched primary carcinomas. *Brit J Cancer* 79 (7-8):1262-1269 (1999)  
IF: 4.8
42. Glasmacher A, Hahn C, Molitor E, Sauerbruch T, **Schmidt-Wolf IGH**, Marklein G. Fungal surveillance cultures during antifungal prophylaxis with itraconazole in neutropenic patients with acute leukaemia. *Mycoses* 42:395-402 (1999)  
IF: 2.2
43. Glasmacher A, Hahn C, Leutner C, Molitor E, Wardelmann E, Losem C, Sauerbruch T, Marklein G, **Schmidt-Wolf IGH**. Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. *Mycoses* 42:443-451 (1999)  
IF: 2.2
44. Searle J, Finke S, Trojanec B, Lefterova P, Micka B, Roigk K, Fehlinger M, **Schmidt-Wolf G**, Polack A, Huhn D, **Schmidt-Wolf IGH**. Effects of human interleukin-2 and interleukin-12 on proliferation of tumor and immunologic effector cells. *Cancer Res Ther Control* 10(1-2) (1999)  
IF: 0.5
45. Glasmacher A, Hahn C, Molitor E, Sauerbruch T, **Schmidt-Wolf IGH**. Itraconazole trough concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-beta-cyclodextrin oral solution or coated-pellet capsules. *Mycoses* 42, 591-600 (1999)  
IF: 2.2

46. **Schmidt-Wolf** IGH, Finke S, Trojaneck B, Denkena A, Lefterova P, Schwella N, Heuft HG, Prange G, Korte M, Takeya M, Dorbic T, Neubauer A, Wittig B, Huhn D. Phase I clinical study applying autologous immunologic effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. *Brit J Cancer* 81(6):1009-1016 (1999)  
IF: 4.8
47. Lefterova P, Märten A, Buttgereit P, Weineck S, Micka B, Scheffold C, Huhn D, **Schmidt-Wolf** IGH. Use of a bispecific anti-CD3xCD19 antibody for targeting of CD3+CD56+ human cytotoxic cells against CD19+ leukemia and lymphoma cells. *Cancer Res Ther Contr* 10:205-215 (1999)  
IF: 0.5
48. Ebert O, Röpke G, Märten A, Lefterova P, Micka B, Buttgereit P, Niemitz S, Trojaneck B, **Schmidt-Wolf** G, Huhn D, Wittig B, **Schmidt-Wolf** IGH. TNF-alpha secretion and apoptosis of lymphocytes mediated by gene transfer. *Cytokines, Cellular & Mol Ther* 5(3):165-173 (1999)  
IF: 1.3
49. Caspari R, Jungck M, Lamberti C, **Schmidt-Wolf** IGH, Friedl W, Propping P. Diagnostik hereditärer kolorektaler Karzinome. *DMW* 125:153-158 (2000)  
IF: 0.5
50. Lamberti C, Jungck M, Caspari R, **Schmidt-Wolf** I, Sauerbruch T. Therapie und Nachsorge der FAP und des HNPCC. *DMW* 125:189-191 (2000)  
IF: 0.5
51. Schroers R, Sinha I, Segall H, **Schmidt-Wolf** IGH, Rooney CM, Brenner MK, Sutton RE, Chen SY. Transduction of human PBMC-derived dendritic cells and macrophages by an HIV-1-based lentiviral vector system. *Molecular Therapy* 1(2), 171-179 (2000)  
IF: 6.2
52. Micka B, Trojaneck B, Niemitz S, Lefterova P, Kruopis S, Huhn D, Wittig B, Schadendorf D, **Schmidt-Wolf** IGH. Comparison of non-viral transfection methods in melanoma primary cultures. *Cytokine* 12(6), 828-833 (2000)  
IF: 2.7
53. Märten A, Schöttker B, Ziske C, Weineck S, Buttgereit P, Huhn D, Sauerbruch T, **Schmidt-Wolf** IGH. Increase of the immunostimulatory effect of dendritic cells by pulsing with CA-19-9 protein. *J Immunother* 23(3):304-310 (2000)  
IF: 4.0
54. Von Ruecker A, **Schmidt-Wolf** I. Strategies to evaluate catabolism and metabolic stress by immunological variables. *Clinical Nutrition* 19(2):147-156 (2000)  
IF: 4.5
55. Lefterova P, Märten A, Buttgereit P, Schakowski F, Micka B, Scheffold C, **Schmidt-Wolf** IGH. Induction of apoptosis in B lymphoma cells by activation with CD40L. *Acta Haematologica* 103(3):168-171 (2000)  
IF: 1.1
56. Flieger D, Spengler U, Beier I, Kleinschmidt R, Sauerbruch T, **Schmidt-Wolf** I. Augmentation of 17-1A induced ADCC by the triple cytokine combination of IFN-alpha, IL-2 and IL-12. *J Immunother* 23(4):480-486 (2000)  
IF: 4.0
57. Lefterova P, Märten A, Buttgereit P, Weineck S, Huhn D, Scheffold C, **Schmidt-Wolf** IGH. Targeting of NK-like T immunologic effector cells against leukemia and lymphoma cells by reverse antibody dependent cellular cytotoxicity. *J Immunother* 23(3):304-310 (2000)  
IF: 4.0

58. Trojaneck B, Niemitz S, Micka B, Lefterova P, **Schmidt-Wolf** IGH. Establishment and characterization of colon carcinoma and renal cell carcinoma primary cultures. *Cancer Biother & Radiopharm* 15(2):169-174 (2000)  
IF: 1.8
59. Märten A, Ziske C, Schöttker B, Renoth S, Weineck S, Buttgereit P, Schakowski F, Klingmüller D, Scheffold C, von Rücker A, Sauerbruch T, **Schmidt-Wolf** IGH. Increase of the immunostimulatory effect of dendritic cells by pulsing with pancreatic or colorectal cancer patient derived serum. *International Journal of Colorectal Disease* 15:197-205 (2000)  
IF: 2.5
60. Flieger D, Renoth S, Beier I, Sauerbruch T, **Schmidt-Wolf** I. Mechanism of cytotoxicity induced by the chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20 expressing lymphoma cell lines. *Cellular Immunology* 204: 55-63 (2000)  
IF: 1.9
61. Flieger D, Kufer P, Beier I, Sauerbruch T, **Schmidt-Wolf** IGH. A bispecific single-chain antibody directed against EpCAM/CD3 mediates efficient cytotoxicity by cytokine-induced killer cells against EpCAM expressing tumor cells. *Cancer Immunol Immunother* 49:441-448 (2000)  
IF: 3.9
62. Flieger D, Spengler U, Beier I, Sauerbruch T, **Schmidt-Wolf** IGH. Prestimulation of monocytes by the cytokines GM-CSF or IL-2 enhances the ADCC of monoclonal antibody 17-1A. *Zeitschrift für Gastroenterologie* 38:615-622 (2000)  
IF: 1.1
63. Zoll B, Lefterova P, Ebert O, Huhn D, von Rücker A, **Schmidt-Wolf** IGH. Modulation of cell surface markers on NK-like T lymphocytes by using interleukin-2, -7 or -12 in vitro stimulation. *Cytokine* 12 (9):1385-1390 (2000)  
IF: 2.7
64. Schlegel U, **Schmidt-Wolf** IGH, Deckert M. Primary CNS lymphoma: Clinical presentation, pathological classification, molecular pathogenesis and treatment. *J Neurol Sciences* 181(1-2):1-12 (2000)  
IF: 2.5
65. Röpke G, Ebert O, Märten A, Lefterova P, Micka B, Buttgereit P, Finke S, Trojaneck B, **Schmidt-Wolf** G, von Rücker A, Huhn D, Wittig B, **Schmidt-Wolf** IGH. Increase in proliferation rate and normalization of TNF-alpha secretion by blockage of gene transfer induced apoptosis using low dose cyclosporine. *Cancer Gene Ther* 7(11):1411-1413 (2000)  
IF: 2.4
66. Lefterova P, Schakowski F, Scheffold C, Huhn D, **Schmidt-Wolf** IGH. Expansion of CD3+CD56+ cytotoxic cells from patients with CLL: In vitro efficacy. *Haematologica* 85(10):1108-1109 (2000)  
IF: 5.8
67. Buttgereit P, Weineck S, Röpke G, Märten A, Brand K, Heinicke T, Caselmann WH, Huhn D, **Schmidt-Wolf** IGH. Efficient gene transfer into lymphoma cells using adenoviral vectors combined with lipofection. *Cancer Gene Ther* 7(8):1145-1155 (2000)  
IF: 2.4
68. Flieger D, Spengler U, Beier I, Sauerbruch T, **Schmidt-Wolf** IGH. Combinations of the cytokines IL-12, IL-2 and IFN-alpha significantly augment whereas the IL-4 suppresses the cytokine-induced antibody dependent cellular cytotoxicity of the monoclonal antibodies 17-1A and BR55-2. *Cytokine* 12(6):756-761 (2000)  
IF: 2.7

69. Scheffold C, Schöttker B, Lefterova P, Csipai M, Glasmacher A, Huhn D, Neubauer A, **Schmidt-Wolf** IGH. Increased sensitivity of myeloid leukemia cell lines: Potential of lovastatin as a bone marrow purging agent. *Acta Haematol* 104(2-3):72-79 (2000)  
IF: 1.1
70. Ziske C, Märten A, Schöttker B, Weineck S, Buttgerit P, Schakowski F, Gorschlüter M, von Rücker A, Scheffold C, Chao N, Sauerbruch T, **Schmidt-Wolf** IGH. DC directly trigger NK-like T lymphocytes: Reversal of resistance of pancreatic carcinoma cells by co-culturing of NK-like T cells with DC pulsed with tumor derived RNA and CA 19-9. *Mol Ther* 3(1):54-60 (2001)  
IF: 6.2
71. Flieger D, Hoff A, Sauerbruch T, **Schmidt-Wolf** IGH. Influence of cytokines, monoclonal antibodies and chemotherapeutic drugs on EpCAM and Lewis<sup>y</sup> antigen expression. *Clin Exp Immunol* 123:9-14 (2001)  
IF:
72. Wittig B, Märten A, Dorbic T, Weineck S, Min H, Lefterova P, Niemitz S, Trojaneck B, Flieger D, Kruopis S, Löffel J, Neubauer A, Albers P, Müller SC, Sauerbruch T, Bieber T, Huhn D, **Schmidt-Wolf** IGH. Therapeutic vaccination against metastatic carcinoma by autologous tumor cells transfected with interleukin-7, GM-CSF and immunostimulatory oligonucleotides: Preclinical results and outcome of a first clinical phase I/II trial. *Human Gene Therapy* 12(3):267-278 (2001)  
IF: 3.1
73. Ziske C, Meybehm M, Sauerbruch T, **Schmidt-Wolf** IGH. Littoral cell angioma as a rare cause of splenomegaly. *Annals of Hematology* 80(1):45-48 (2001)  
IF:
74. Märten A, Ziske C, Schöttker B, Weineck S, Buttgerit P, Schakowski F, von Rücker A, Scheffold C, Sauerbruch T, **Schmidt-Wolf** IGH. Transduction of DC with the CIITA gene: Increase of immunostimulatory activity of DC. *Cancer Gene Therapy* 8/3:211-219 (2001)  
IF: 3.1
75. Pels H, Glasmacher A, **Schmidt-Wolf** IGH, Schlegel U. Therapie primärer cerebraler Lymphome. *Aktuelle Neurologie* 28:189-194 (2001)  
IF: 0.3
76. Schakowski F, Gorschlüter M, Junghans C, Schroff M, Buttgerit P, Ziske C, Schöttker B, König-Merediz SA, Sauerbruch T, Wittig B, **Schmidt-Wolf** IGH. A novel minimal-size vector (MIDGE) improves transgene expression in colon carcinoma cells and avoids transfection of undesired DNA. *Mol Ther* 3(5):793-800 (2001)  
IF: 6.2
77. Schlegel U, Pels H, Glasmacher A, Kleinschmidt R, **Schmidt-Wolf** I, Helmstaedter C, Fließbach K, Deckert-Schlüter M, Van Roost D, Fimmers R, Bode U, Klockgether T. Combined systemic and intraventricular chemotherapy in primary CNS lymphoma: a pilot study. *J Neurol Neurosurg Psychiatry* 71(1):118-122 (2001)  
IF: 6.8
78. Märten A, Ziske C, Weineck S, Buttgerit P, Lefterova P, Klingmüller D, von Rücker A, Scheffold C, Sauerbruch T, **Schmidt-Wolf** IGH. Priming of NK-like T lymphocytes by addition of dendritic cells pulsed with CEA protein and patient serum containing CEA. *Cancer Research, Therapy & Control* 11:157-166 (2001)  
IF: 0.5
79. Gorschlüter M, Glasmacher A, Hahn C, Schakowski F, Ziske C, Molitor E, Marklein G, Sauerbruch T, **Schmidt-Wolf** IGH. Clostridium difficile infection in patients with neutropenia. *Clinical Infectious Diseases* 33:786-791 (2001)

- IF: 8.9
80. Gorschlüter M, Ziske C, Glasmacher A, **Schmidt-Wolf** IGH. Current clinical and laboratory strategies to augment the efficiency of immunotherapy in multiple myeloma. *Clin Cancer Research* 7(8):2195-2204 (2001)  
IF: 8.7
81. Buttgereit P, Schakowski F, Märten A, Brand K, Renoth S, Ziske C, Schöttker B, Ebert O, Schroers R, **Schmidt-Wolf** IGH. Effects of adenoviral wild-type p53 gene transfer in p53- mutated lymphoma cells. *Cancer Gene Therapy* 8(6):430-439 (2001)  
IF: 3.1
82. Gorschlüter M, Glasmacher A, Hahn C, Leutner C, Marklein G, Remig J, **Schmidt-Wolf** IGH, Sauerbruch T. Severe abdominal infections in neutropenic patients. *Cancer Invest* 19(7):669-677 (2001)  
IF: 2.2
83. Märten A, Renoth S, von Lilienfeld-Toal M, Buttgereit P, Schakowski F, Glasmacher A, Sauerbruch T, **Schmidt-Wolf** IGH. Enhanced lytic activity of cytokine-induced killer cells against multiple myeloma cells after co-culture with idiotype-pulsed dendritic cells. *Haematologica* 86(10):1029-1037 (2001)  
IF: 5.8
84. von Lilienfeld-Toal M, Ebert O, Theuerkauf I, Glasmacher A, **Schmidt-Wolf** IGH. Small bowel obstruction in acute myelogenous leukemia: Stenosis or paralysis? *Annals Hematol* 80:611-613 (2001)  
IF: 2.6
85. Korfel A, Finke J, **Schmidt-Wolf** I, Thiel E. 5. Report on workshop: Primary CNS lymphoma. *Ann Hematol.* 80 Suppl 3:B20-23 (2001)  
IF: 2.6
86. Märten A, Ziske C, Schöttker B, Renoth S, Weineck S, Buttgereit P, Schakowski F, von Rücker A, Sauerbruch T, **Schmidt-Wolf** IGH. Interactions between DC and CIK cells lead to an activation of both populations. *J Immunother* 24(6):502-510 (2001)  
IF: 4.0
87. Märten A, Greten T, Ziske C, Schöttker B, Renoth S, Schöttker B, Buttgereit P, Schakowski F, von Rücker A, Sauerbruch T, **Schmidt-Wolf** IGH. Generation of activated and antigen-specific T cells with cytotoxic activity after coculture with dendritic cells. *Cancer Immunol Immunother* 51:25-32 (2002)  
IF: 3.9
88. Gorschlüter M, Hahn C, Ziske C, Mey U, Schöttker B, Molitor E, Becker S, Marklein G, Sauerbruch T, **Schmidt-Wolf** IGH, Glasmacher A. Low frequency of enteric infections by salmonella, shigella, yersinia and campylobacter in patients with acute leukemia. *Infection* 30(1):22-25 (2002)  
IF: 2.6
89. **Schmidt-Wolf** G, **Schmidt-Wolf** IGH. Immunomodulatory gene therapy for haematological malignancies. *Brit J Haematol* 117(1):23-32 (2002)  
IF: 5.0
90. Ziske CG, Schöttker B, Gorschlüter M, Mey U, Kleinschmidt R, Schlegel U, Sauerbruch T, **Schmidt-Wolf** IGH. Acute transient encephalopathy after paclitaxel infusion: report of three cases. *Annals of Oncology* 13:629-631 (2002)  
IF: 7.0
91. Layer G, Sander W, Träger F, Block W, Ziske C, **Schmidt-Wolf** IGH, Schild HH, Ko Y. Magnetic resonance findings in the bone marrow of the lumbar spine in patients during G-CSF therapy in comparison to malignant bone marrow infiltrations. In press, *Cancer*  
IF: 5.2



92. Springer W, Decker D, Daufeldt S, Decker P, **Schmidt-Wolf** IGH, Hirner A, von Ruecker A. Human growth hormone down-regulates apoptosis and increases superoxide production in neutrophils from patients undergoing major vascular surgery. In press, *Annals of Surgery* (07/02)  
IF: 8.3
93. Gorschlüter M, Marklein G, Hofling K, Clarenbach R, Baumgartner S, Hahn C, Ziske C, Mey U, Heller R, Eis-Hübinger AM, Sauerbruch T, **Schmidt-Wolf** IGH, Glasmacher A. Abdominal infections in patients with acute leukaemia: a prospective study applying ultrasonography and microbiology. *Brit J Haematol* 117(2):351-358 (2002)  
IF: 5.0
94. Buttgereit P, **Schmidt-Wolf** IGH. State-of-the-art review. Gene therapy of lymphoma. *J Hematother & Stem Cell Res* 11(3): 457-467 (2002)  
IF: 2.5
95. **Schmidt-Wolf** IGH, Rockstroh JK, Schlegel U, Pels H, Weiss R, Huhn D. New aspects in the treatment of AIDS-related lymphoma. *Eur J Med Research* 7(7):295-303 (2002)  
IF: 1.5
96. Reinhard G, Märten A, Kiske M, Feil F, Bieber T, **Schmidt-Wolf** IGH. Generation of dendritic cell-based vaccines for cancer therapy. *Brit J Cancer* 86:1529-1533 (2002)  
IF: 4.8
97. Märten A, Renoth S, **Schmidt-Wolf** IGH. Increase of the stimulatory effect of dendritic cells by pulsing with apoptotic bodies transfected with the MHC class II gene. *Mol Immunol* 39:395-398 (2002)  
IF: 3.0
98. Ziske C, Gorschlüter M, Mey U, Offergeld R, Glasmacher A, **Schmidt-Wolf** IGH. Sequential high-dose chemotherapy with autologous stem cell support in patients with limited-stage small cell lung cancer. *Anticancer Research* 22 (6) 3723-3726 (2002)  
IF: 1.8
99. Märten A, Flieger D, Renoth S, Weineck S, Albers P, Compes M, Schöttker B, Ziske C, Engelhart S, Hanfland P, Krizek L, Faber C, von Rücker A, Müller S, Sauerbruch T, **Schmidt-Wolf** IGH. Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: Preclinical results and outcome of a first clinical phase I/II trial. *Cancer Immunol Immunother* 51:637-644 (2002)  
IF: 3.9
100. Abken H, Hombach A, Reinhard G, Märten A, Schlimper C, Glasmacher A, Bieber T, **Schmidt-Wolf** IGH. Cellular immunotherapy after autologous hematopoietic stem cell transplantation: Experimental strategies and clinical experiences. *Leukemia & Lymphoma* 44(4): 583-592 (2003)  
IF: 2.9
101. Mey U, Glasmacher A, Hahn C, Gorschlüter M, Ziske B, Mergelsberg M, Sauerbruch T, **Schmidt-Wolf** IGH. Evaluation of an ultrasound-guided technique for central venous access via the internal jugular vein in 493 patients. *Supp Care Cancer* 11:148-155 (2003)  
IF: 2.4
102. **Schmidt-Wolf** IGH, Rockstroh JK, Schüller H, Hirner A, Grohe C, Müller-Hermelink HK, Huhn D. Malignant thymoma: Current status of classification and multimodality treatment. *Annals Hematol* 82(2):69-76 (2003)  
IF: 2.6
103. Klaus Fliessbach, Horst Urbach, Christoph Helmstaedter, Hendrik Pels, Axel Glasmacher, Jürgen A. Kraus, Thomas Klockgether, Ingo **Schmidt-Wolf**, Uwe Schlegel. Cognitive Performance and MRI Findings after High Dose Systemic and Intraventricular Chemotherapy for Primary CNS Lymphoma. *Archives of Neurology* 60:563-568 (2003)

- IF: 7.4
104. Mey U, Strehl J, Gorschlüter M, Ziske C, Sauerbruch T, Glasmacher A, Pralle H, **Schmidt-Wolf** IGH. Recent advances in the treatment of hairy cell leukemia. *The Lancet Oncology* 4: 86-94 (2003); IF 24,7  
IF: 45.2
105. **Schmidt-Wolf** GD, **Schmidt-Wolf** IGH. Non-viral and hybrid vectors in human gene therapy: an update. *Trends Molecular Medicine* 9(2):67-72 (2003)  
IF: 9.5
106. Mey U, Gorschlüter M, Ziske C, Kleinschmidt R, Glasmacher A, **Schmidt-Wolf** IGH. Weekly docetaxel in patients with pretreated metastatic breast cancer: a phase II trial. *Anticancer Drugs* 14:233-238 (2003)  
IF: 1.8
107. Märten A, Renoth S, Heinicke T, Albers P, Pauli A, von Lilienfeld-Toal M, Caspari R, Flieger D, Hanfland P, von Rücker A, Eis-Hübinger AM, Müller S, Schwaner I, Lohmann U, Heylmann G, Sauerbruch T, **Schmidt-Wolf** IGH. Allogeneic dendritic cells fused with tumor cells: Preclinical results and outcome of a first clinical phase I/II trial in patients with renal cell carcinoma. *Hum Gene Ther* 4(5):483-494 (2003)  
IF: 3.8
108. Gorschlüter M, Hahn C, Fixon A, Mey U, Ziske C, Molitor E, Horre R, Sauerbruch T, Marklein G, **Schmidt-Wolf** IGH, Glasmacher A. Piperacillin-tazobactam is more effective than ceftriaxone plus gentamicin in febrile neutropenic patients with haematologic malignancies: a randomized comparison. *Supportive Care in Cancer* 11:362-370 (2003)  
IF: 2.4
109. **Schmidt-Wolf** GD, **Schmidt-Wolf** IGH. Gene therapy for hematological malignancies. *Clinical and Experimental Medicine* 3 (1):4-14 (2003)  
IF: 3.0
110. Palmedo H, Manka-Waluch A, Albers P, **Schmidt-Wolf** IGH, Reinhardt M, Ezziddin S, Joe A, Roedel R, Fimmers H, Knapp FF, Guhlke S, Biersack HJ. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: Randomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 HEDP. *J Clin Oncol* 21(15):2869-2875 (2003)  
IF: 18.4
111. Steigerwald R, Rabe C, Schmitz V, **Schmidt-Wolf** IGH, Alt M, Caselmann WH. Requirements for adeno-associated virus-derived non-viral vectors to achieve stable and site-specific integration of plasmid DNA in liver carcinoma cells. *Digestion* 68:13-23 (2003)  
IF: 2.1
112. **Schmidt-Wolf** IGH, Rockstroh JK, Schlegel U, Pels H, Mey U, Strehl J, Weiss R, Huhn D. Treatment options of AIDS-related lymphoma. *Expert Opinion on Pharmacotherapy* 4(8):1331-1343 (2003)  
IF: 3.5
113. Ziske C, Mezger J, Jiménez C, Kleinschmidt R, Pels H, Schlegel U, **Schmidt-Wolf** IGH. High dose chemotherapy with autologous peripheral blood stem cell support in an adult patient with a recurrent AFP-producing intracranial germinoma. *German Medical Science* Vol.1, Doc03, 20030701 (2003)  
IF: 0
114. **Schmidt-Wolf** IGH, Pels H (contributed equally), Glasmacher A, Schulz H, Engert A, Diehl V, Zellner A, Schackert G, Reichmann H, Kroschinsky F, Vogt-Schaden M, Egerer G, Bode U, Deckert M, Fimmers R, Helmstaedter C, Althaus A, Atasoy A, Klockgether

- T, Schlegel U. PCNSL: Results of a pilot / Phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. *J Clin Oncol* 21(24):4489-4495 (2003)  
IF: 18.4
115. Ziske C, Schlie C, Gorschlüter M, Glasmacher A, Mey U, Strehl J, Sauerbruch T, **Schmidt-Wolf** IGH. Prognostic value of CA19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. *Brit J Cancer* 89(8):1413-1417 (2003)  
IF: 4.8
116. Gross C, **Schmidt-Wolf** IGH, Nagaraj S, Ellwart J, Kunz-Schughart L, Multhoff G. Heat shock protein 70-reactivity is associated with increased cell surface density of CD94/CD56 on primary natural killer cells. *Cell Stress & Chaperones* 8(4):348-360 (2003)  
IF: 3.2
117. Engelhart S, Hanfland J, Glasmacher A, Krizek L, **Schmidt-Wolf** IGH, Exner M. Impact of portable air filtration units on exposure of haematology-oncology patients to airborne *Aspergillus fumigatus* spores under field conditions. *J Hospital Infection* 54:300-304 (2003)  
IF: 2.5
118. Goldschmidt H, Sonneveld P, Cremer FW, van der Holt B, Westveer P, Bretkreutz I, Benner A, Glasmacher A, **Schmidt-Wolf** IGH, Martin H, Hoelzer D, Ho AD, Lokhorst H. The joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients. *Ann Hematol* 82 (10): 654-659 (2003)  
IF: 2.6
119. Sievers E, Albers P, **Schmidt-Wolf** IGH, Märten A. Telomerase pulsed dendritic cells for immunotherapy of renal cell carcinoma. *J Urology* 171:114-119 (2004)  
IF: 4.4
120. Schmidt T, Ziske C, Märten A, Endres S, Tiemann K, Schmitz V, Gorschlüter M, Schneider C, Sauerbruch T, **Schmidt-Wolf** IGH. Intratumoral immunization with tumor RNA-pulsed dendritic cells confers antitumor immunity in a C57BL/6 pancreatic murine tumor model. *Cancer Res* 63:8962-8967 (2003)  
IF: 9.3
121. Schneider C, Schmidt T, Ziske C, Tiemann K, Lee KM, Uhlinsky V, Behrens P, Sauerbruch T, **Schmidt-Wolf** IGH, Mühlradt PF, Schmidt J, Märten A. Tumor suppression induced by macrophage activating lipopeptide MALP-2 in an ultrasound guided pancreatic carcinoma mouse model. *GUT* 53:355-361 (2004)  
IF: 14.7
122. Strehl J, Mey U, Glasmacher A, Djulbegovic B, Mayr C, Gorschlüter M, Mayr C, Ziske C, **Schmidt-Wolf** IGH. High-dose chemotherapy followed by ASCT as first-line therapy in aggressive NHL: a meta-analysis. *Haematologica* 88(11):1304-1315 (2003)  
IF: 5.8
123. Glasmacher A, Prentice A, Gorschlüter M, Engelhart S, Hahn C, Djulbegovic B, **Schmidt-Wolf** IGH. Itraconazole prevents invasive fungal infection in neutropenic patients treated for haematological malignancies: Evidence from a meta-analysis of 3597 patients. *J Clin Oncol* 21 (24) 4615-4626 (2003)  
IF: 18.4
124. Schakowski F, Buttgerit P, Mazur M, Märten A, Schöttker B, **Schmidt-Wolf** IGH. A novel non-viral method for transfection of primary leukemia cells and cell lines. *Genetic Vaccines and Therapy*, Vol. 2, <http://www.gvt-journal.com/content/2/1/1> (2004)  
IF: 2.1

125. Rabe C, Mey U, Paashaus M, Musch A, Tasci S, Glasmacher A, **Schmidt-Wolf** IGH, Sauerbruch T, Dumoulin FL. Outcome of patients with AML and pulmonary infiltrates requiring invasive mechanical ventilation – a retrospective analysis. *J Crit Care* 19 (1):29-35 (2004)  
IF: 2.0
126. Glasmacher A, Goldschmidt H, Mezger J, Haferlach T, **Schmidt-Wolf** IGH, Gieseler F. Oral idarubicin, dexamethasone and vincristine in the treatment of multiple myeloma: final analysis of a phase II trial. *Haematologica* 89(3):371-373 (2004)  
IF: 5.8
127. Nagaraj S, Ziske C, **Schmidt-Wolf** IGH. Dendritic cell, the immunotherapeutic cell. *Indian J Med Res* 119:133-138 (2004)  
IF: 1.4
128. Linnebank M, Schmidt S, Kölsch H, Linnebank A, Heun R, **Schmidt-Wolf** IGH, Glasmacher A, Fliessbach K, Klockgether T, Schlegel U, Pels H. The methionine synthase polymorphism D919G alters susceptibility to primary central nervous system lymphoma. *Brit J Cancer* 90:1969-1971 (2004)  
IF: 4.8
129. Ziske C, Nagaraj S, Märten A, Gorschlüter M, Strehl J, Sauerbruch T, Abraham NG, **Schmidt-Wolf** IGH. Retroviral interferon-alpha gene transfer combined with gemcitabine acts synergistically via cell cycle alteration in human pancreatic carcinoma cells implanted orthotopically in nude mice. *J Interferon Cytokine Res* 24(8):490-496 (2004)  
IF: 2.0
130. Schulz H, Pels H, **Schmidt-Wolf** IGH, Zeelen U, Germing U, Engert A. Intraventricular treatment of relapsed CNS lymphomas with the anti-CD20 antibody rituximab. *Haematologica* 89(6): 753-754 (2004)  
IF: 5.8
131. Leo E, Scheuer L, **Schmidt-Wolf** IGH, Kerowgan M, Schmitt C, Leo A, Baumbach T, Kraemer A, Benner, Parwaresch R, Ho AD. Significant thrombocytopenia associated with the addition of rituximab to a combination of fludarabine and cyclophosphamide in the treatment of relapsed follicular lymphoma. *European J Hematol* 73:251-257 (2004)  
IF: 2.1
132. Schmidt S, Schneider T, **Schmidt-Wolf** I, Ko Y, Schlegel U, Klockgether T, Hertfelder HJ. C1-Inhibitor activity and plasma concentrations in patients with monoclonal gammopathies: implications for treatment with recombinant interferon-beta 1b. *Mult Scler. Apr*;10(2):243-244 (2004)  
IF: 4.2
133. Von Lilienfeld-Toal M, Dietrich MP, Glasmacher A, Lehmann L, Breig P, Hahn C, **Schmidt-Wolf** IGH, Marklein G, Schroeder S, Stuber F. Markers of bacteremia in febrile neutropenic patients with hematological malignancies: procalcitonin and IL-6 are more reliable than CRP. *Europ J Clin Microbiol Infect Dis* 23(7):539-544 (2004)  
IF: 2.7
134. Nagaraj S, Ziske C, **Schmidt-Wolf** IGH. Human CIK cells have enhanced in vitro cytolytic activity via non-viral IL-2 gene transfer. *GVT* 2:12 [www.gvt-journal.com/content/2/1/12](http://www.gvt-journal.com/content/2/1/12) (2004)  
IF: 2.1
135. Mehrle S, Frank S, Schmidt J, **Schmidt-Wolf** IGH, Märten A. SAP and SLAM expression in anti-CD3 activated lymphocytes correlates with cytotoxic activity. *Immunol Cell Biol* 83:33-39 (2005)  
IF: 4.2

136. Ebert O, Wilbert D, Buttgereit P, Ziske C, Flieger D, Sauerbruch T, **Schmidt-Wolf IGH**. Effects of recombinant IL-2 and IL-12 in human B lymphoma cells on co-cultured lymphocytes. <http://www.gvt-journal.com/content/2/1/15>  
IF: 2.1
137. Pels H, Montesinos-Rongen M, Schaller C, Schlegel U, **Schmidt-Wolf IGH**, Wiestler OD, Deckert M. VH gene sequence analysis in PCNSL: Molecular phenotype correlated with clinical outcome. In Druck, J Neurol Sci  
IF: 2.5
138. Linnebank M, Pels H, Kleczar N, Farmand S, Fliessbach K, Urbach H, Orlopp K, Klockgether T, **Schmidt-Wolf IGH**, Schlegel U. MTX-induced white matter changes are associated with polymorphisms of methionine metabolism. *Neurology* 64:912-913 (2005)  
IF: 8.2
139. Bonn O, **Schmidt-Wolf G**, Risse R, Glasmacher A, Kleinschmidt R, **Schmidt-Wolf IGH**. Vindesine and etoposide: a practical and well tolerated therapy for elderly patients in reduced clinical condition with extensive stage small cell lung cancer (SCLC). (q:\PubSCLCMSM2.doc). *Medical Science Monitor* 11(2): PI19-21 (2005)  
IF:
140. Fliessbach K, Helmstaedter C, Urbach H, Althaus A, Pels H, Linnebank M, Juergens A, Glasmacher A, **Schmidt-Wolf IGH**, Klockgether T, Schlegel U. Neuropsychological outcome after chemotherapy for primary CNS lymphoma: a prospective study. *Neurology* 64(7):1184-1188 (2005)  
IF: 8.2
141. Erhardt M, Gorschlüter M, Sager J, Ziske C, Strehl J, von Lilienfeld-Toal M, **Schmidt-Wolf IGH**. Transfection of human monocyte-derived DC with CpG oligonucleotides. *Immunology and Cell Biology* 83, 278-285 (2005)  
IF: 4.2
142. Von Lilienfeld-Toal M, Sievers E, Bodemüller V, Mihailescu C, Märten A, Gorschlüter M, **Schmidt-Wolf IGH**. Coculture with dendritic cells promotes proliferation of gamma/delta T cells. *Immunol Lett* 99(1):103-108 (2005)  
IF: 2.5
143. Gorschlüter M, Mey U, Strehl J, Ziske C, Schepke M, **Schmidt-Wolf IGH**, Sauerbruch T, Glasmacher A. Neutropenic enterocolitis in adults: Systematic analysis of evidence quality. *Eur J Haematol* 75(1):1-13 (2005)  
IF: 2.1
144. Schmidt J, Ryschich E, Sievers E, **Schmidt-Wolf IGH**, Büchler M, Märten A. Telomerase-specific T-cells kill pancreatic tumor cells in vitro and in vivo. *Cancer* 15;106(4):759-764 (2006)  
IF: 5.2
145. H. Palmedo, H. Bender, H. Urbach, U. Schlegel, I.G.H. **Schmidt-Wolf**, A. Matthies, A. Joe, J. Bucerius, H.-J. Biersack, H. Pels. Primary diagnosis and therapeutic monitoring of primary central nervous system lymphoma with FDG-PET in immunocompetent patients: correlation with MRI and clinical follow-up. *Eur J Nucl Med Mol Imaging*, Oct 12 (2005) IPF 3,9  
IF:
146. Glasmacher A, von Lilienfeld-Toal M, Schulte S, Hahn C, **Schmidt-Wolf IGH**, Prentice A. An evidence-based evaluation of important aspects of empiric antibiotic therapy in febrile neutropenic patients. *Clin Microbiol Infect* 11:17-23 (2005)  
IF:
147. Hombach A, Schlimper C, Sievers E, Frank S, Schild HH, Sauerbruch T, **Schmidt-Wolf IGH**, Abken H. A recombinant anti-CEA immunoreceptor with combined CD3zeta –

- CD28 signalling targets T cells from colorectal cancer patients against their tumor cells. *GUT*, Dec 2 (2005)  
IF: 14.7
148. Rudolf Weiss, Paris Mitrou, Keikawus Arastéh, Dirk Schuermann, Hannelore Seibt, Birgit Ross, Thomas Kubin, Markus Hentrich, Ulrich Duehrsen, Hans Pees, Bernhard Fleischer, Christoph Heese, Ingo **Schmidt-Wolf**, Ioannis Anagnostopoulos, Dieter Huhn. AIDS-related lymphoma (ARL): Simultaneous treatment with CHOP chemotherapy and with highly active antiretroviral therapy (HAART) is save and improves survival. Results of the German multicenter trial for the treatment of AIDS-related lymphomas. *Cancer* 106(7):1560-1568 (2006)  
IF: 5.2
149. Mey U, Orlopp KS, Flieger D, Strehl J, Ho AD, Hensel M, Bopp C, Gorschlüter M, Wilhelm M, Birkmann J, Kaiser U, Neubauer A, Florschütz A, Hahn C, Glasmacher AG, **Schmidt-Wolf** IGH. DHAP in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive NHL. *Cancer Investigation* 24 (6):593-600 (2006)  
IF: 2.2
150. **Schmidt-Wolf** IGH, Glasmacher A, Hahn-Ast C, Jüttner A, Schnurr T, Cremer F, Moehler T, Goldschmidt H, Busert B, Schubert R, Schwanitz G. Chromosomal aberrations in 130 patients with multiple myeloma studied by interphase FISH: diagnostic and prognostic relevance. *Cancer Genetics Cytogenetics* 167:20-25 (2006)  
IF: 1.9
151. Glasmacher A, Hahn C, Hoffmann F, Naumann R, Goldschmidt H, von Lilienfeld-Toal M, Orlopp K, **Schmidt-Wolf** IGH, Gorschlüter M. A systematic review of phase II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. *Brit J Haematol* 132(5):584-593 (2006)  
IF: 5.0
152. Gonzalez-Carmona MA, Märten A, Hoffmann P, Schneider C, Sievers E, **Schmidt-Wolf** IGH, Sauerbruch T, Caselmann WH. Patient-derived DCs transduced with an AFP-encoding adenovirus and co-cultured with autologous cytokine-induced lymphocytes induce a specific and strong immune response against hepatocellular carcinoma cells. *Liver International*, 26:369-379 (2006)  
IF: 4.9
153. Gorschlüter M, Mey U, Strehl J, Schmitz V, Wardelmann E, Ziske C, **Schmidt-Wolf** IGH, Glasmacher A., v. Lilienfeld-Toal, M. Invasive fungal infections in neutropenic enterocolitis: A systematic analysis of pathogens, incidence, treatment and mortality in adult patients. *BMC Infectious Diseases*, in Druck.  
IF: 2.6
154. Orlopp K, **Schmidt-Wolf** IGH, Urbach H, Schlegel U. Akute zentralnervöse Symptome bei onkologischen Patienten. *Der Internist* 46(1):19-29 (2005)#  
IF: 0.3
155. Gorschlüter M, Mey U, Glasmacher A, Schwerdtfeger R, **Schmidt-Wolf** IGH. Acute myeloid leukemia with near-triploid karyotype and extramedullary involvement of mediastinum. *Bone Marrow Transplant* 36(12):1107 (2005)  
IF: 3.6
156. Lamberti C, Di Blasi K, Archut D, Fimmers R, Mathiak M, Bollmann M, Vogel J, Kindermann D, Mezger J, **Schmidt-Wolf** IGH, Sauerbruch T. Population-Based Registration of Unselected Colorectal Cancer Patients: Five-Year Survival in the Region of Bonn/Rhine-Sieg, Germany. *Z Gastroenterol* 43:149-154 (2005)  
IF: 1.1

157. Link BC, Ziske CG, Schepke M, **Schmidt-Wolf** IGH, Sauerbruch T. Total ascitic fluid leukocyte count for reliable exclusion of spontaneous bacterial peritonitis in patients with ascites. *Eur J Gastroenterol Hepatol* 18(2):181-186 (2006)  
IF: 2.3
158. Lamberti C, Lundin S, Bogdanow M, Gorschlüter M, **Schmidt-Wolf** IGH, Sauerbruch T. Adjuvant and palliative chemotherapy of colorectal cancer in Germany outside controlled trials. *DMW* 131 (10):485-490 (2006)  
IF: 0.5
159. Von Lilienfeld-Toal M, Nattermann J, Feldmann G, Sievers E, Frank S, Strehl J, **Schmidt-Wolf** IGH. Activated gamma delta T cells express the natural cytotoxicity receptor Nkp44 and show cytotoxic activity against myeloma cells. *Clinical Exper Immunol* 144(3):528-533 (2006)  
IF: 3.0
160. Märten A, Sievers E, Albers P, Müller S, Franchy C, von Ruecker A, Strunk H, Schild HH, Schmiedel A, Sommer T, Sauerbruch T, **Schmidt-Wolf** IGH. Telomerase-pulsed dendritic cells: Preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. *German Medical Science* 4: Doc02 (2006)  
IF: 0
161. Nagaraj S, Ziske C, Strehl J, Messmer D, Sauerbruch T, **Schmidt-Wolf** IGH. Dendritic cells pulsed with alpha-galactosylceramide induce antitumor immunity against pancreatic cancer in vivo. *International Immunology* 18(8):1279-1283 (2006)  
IF: 2.5
162. Telusma G, Datta S, Mihajlov I, Ma W, Li J, Yang H, Newman W, Messmer BT, Minev B, **Schmidt-Wolf** IGH, Tracey KJ, Chiorazzi N and Messmer D. Dendritic cell activating peptides induce distinct cytokine profiles. *Int Immunol* 18(11): 1563-1573 (2006)  
IF: 2.5
163. Geiser F, Hahn C, Conrad R, Liedtke R, Sauerbruch T, **Schmidt-Wolf** I, Glasmacher A. Interaction of psychosocial factors and the effect of epoetin alfa treatment in cancer patients on hemoglobin and fatigue. *Supportive Care in Cancer* 15(3):273-8 (2007)  
IF: 2.4
164. Mey U, Olivieri A, Orlopp K, Rabe C, Strehl J, Gorschlüter M, Hensel M, Flieger D, Glasmacher A, **Schmidt-Wolf** IGH. DHAP in combination with rituximab versus DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B-cell lymphoma: a matched-pair analysis. *Leukemia & Lymphoma* 47(12):2558-2566 (2006)  
IF: 2.9
165. Messmer D, Hatsukari I, Hitosugi N, **Schmidt-Wolf** IGH, Singhal PC. Morphine reciprocally regulates IL-10 and IL-12 production by monocyte-derived human DC and enhances T cell activation. *Mol Med* 12(11-12):284-290 (2006)  
IF: 4.5
166. Erhardt M, **Schmidt-Wolf** IGH, Sievers E, Frank S, Strehl J, v. Lilienfeld-Toal M, Gorschlüter M. Antitumoral capabilities of effector cells after interferon- $\alpha$  or CpG-motif treatment of cocultured dendritic cells. *Arch Immunol Ther Exp* 54 (6): 403-409 (2006)  
IF: 3.2
167. Lamberti C, Mangold E, Pagenstecher C, Jungck M, Schwering D, Bollmann M, Vogel J, Kindermann D, Nikorowitsch R, Friedrichs N, Schneider B, Houshdaran F, **Schmidt-Wolf** IGH, Friedl W, Propping P, Sauerbruch T, Büttner R, Mathiak M. Frequency of hereditary non-polyposis colorectal cancer among unselected patients with colorectal cancer in Germany. *Digestion*. 2006;74(1):58-67.  
IF: 2.1

168. Schakowski F, Gorschlüter M, Buttgereit P, Märten A, von-Lilienfeld-Toal M, Junghans C, Schroff M, König-Meridiz SA, Ziske C, Strehl J, Sauerbruch T, Wittig B, **Schmidt-Wolf** IGH. Minimal size MIDGE vectors improve transgene expression in vivo. *In Vivo* 21:17-24 (2007)  
IF: 1.0
169. Sievers E, Haferkamp A, Dreimüller P, **Schmidt-Wolf** IGH, Schmidt J, Märten A. Characterization of primary renal carcinoma cultures. *Urologia Internationalis*, in Druck  
IF: 1.4
170. Mey U, Maier A, **Schmidt-Wolf** IGH, Ziske C, Forstbauer H, Banat GA, Reber M, Strehl J, Gorschlüter M. Pegfilgrastim as hematopoietic support for dose-dense chemoimmunotherapy with R-CHOP-14 as first-line therapy in elderly patients with diffuse large B cell lymphoma. *Supportive Care in Cancer*, online, 2007 Jan 19  
IF: 2.4
171. Courts C, Montesinos-Rongen M, Martin-Subero JI, Brunn A, Bechtel D, Zühlke-Jenisch R, Pels H, Jürgens A, Schlegel U, **Schmidt-Wolf** IGH, Schaller C, Reifenberger G, Sabel M, Warnecke-Eberz U, Wiestler OD, Küppers R, Siebert R, Deckert M. Transcriptional profiling of the NF- $\kappa$ B pathway identifies a subgroup of primary lymphoma of the central nervous system with low BCL10 expression and unfavorable prognosis. *J Neuropathol Exp Neurol* 66(3):230-237 (2007)  
IF: 3.8
172. Gorschlüter M, Glasmacher A, Sarazin S, Hackbarth F, Hoebert E, Orlopp K, **Schmidt-Wolf** IGH, Mey U. CD4+ T lymphocyte counts after autologous transplantation in multiple myeloma. A retrospective study. *Leukemia and Lymphoma*, 48(3):506-512 (2007)  
IF: 2.9
173. Hedde JP, Neuhaus T, Schüller H, Metzler U, **Schmidt-Wolf** IGH, Kleinschmidt R, Loosem C, Lange O, Grohé C, Stier S, Ko YD. A phase I/II Trial of Topotecan and Radiation Therapy for Brain Metastases in Patients with Solid Tumors. *Int J Radiat Oncol Biol Phys*. 2007 Mar 20  
IF: 4.3
174. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutherlet K, Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein WO, Niedergethmann M, **Schmidt-Wolf** IGH, Roll L, Doerken B, Riess H. Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer: A Randomized Controlled Trial. *JAMA* 297 (3): 267-277, 2007.  
IF: 35.3
175. Lorch A, Rick O, Hartmann JT, Kollmansberger C, Metzner B, **Schmidt-Wolf** IGH, Glasmacher A, Berdel WE, Schirren R, Beyer J, Bokemeyer C. Single versus sequential high dose chemotherapy (HDCT) in patients with relapsed or refractory-germ cell tumors *JCO* 25(19):2778-2784, 2007.  
IF: 18.4
176. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, Mc Dermott D, Bodrogi I, Kovacevic Z, Lesovoy V, **Schmidt-Wolf** IGH, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer R. Temsirolimus, Interferon alfa, or both for Advanced Renal-Cell Carcinoma. *NEJM (The New England Journal of Medicine)* 356(22):2271-2281 (2007)  
IF: 55.9
177. Breitkreutz I, Lokhorst HM, Raab MS, van der Holt BV, Cremer FW, Herrmann D, Glasmacher A, **Schmidt-Wolf** IGH, Blau IW, Martin H, Salwender H, Hänel A,



- Sonneveld P, Goldschmidt H. Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide on peripheral blood stem cell collection yield. *Leukemia* 1-6, 2007 Mar 22  
IF: 10.4
178. Flieger D, Varvenne M, Kleinschmidt R, **Schmidt-Wolf** IGH. Influence of immunomodulatory drugs on the cytotoxicity induced by monoclonal antibody 17-1A and interleukin-2. *Cellular Immunol* 246(1):26-33, 2007.  
IF: 1.9
179. Mey UJM, Jha V, Strehl JW, Gorschlüter M, Rabe C, Hoebert E, Popp H, **Schmidt-Wolf** IGH. High dose chemotherapy with autologous stem cell transplantation in diffuse large B-cell lymphoma. *GMS* 5:2007  
IF: 0
180. Gütgemann S, Frank S, Strehl J, **Schmidt-Wolf** IGH. Cytokine-induced killer cells are type II natural killer T cells. *GMS*, <http://www.egms.de/en/gms/2007-5/000043.shtml>  
IF: 0
181. Ziske C, Tiemann K, Schmidt T, Nagaraj S, Märten A, Schmitz V, Clarenbach R, Sauerbruch T, **Schmidt-Wolf** IGH. Real-time compound imaging allows percutaneous initiation and surveillance in an orthotopic murine pancreatic cancer model. *Pancreas* 2008 Mar;36(2):146-52.  
IF: 3.0
182. Shimomura A, v. Lilienfeld-Toal M, Balta Z, Schroers E, **Schmidt-Wolf** IGH, Büttner R, von Rücker A, Gütgemann I. Lack of Surface and Cytoplasmic Immunoglobulin Light Chains in a HIV-related Burkitt Lymphoma. *Ann Hematol*, in Druck  
IF: 2.6
183. H.M. Lokhorst, I. **Schmidt-Wolf**, P. Sonneveld, B. van der Holt, H. Martin, R. Barge, U. Bertsch, J. Schlenzka, G. Bos, A. Croockewit, S. Zweegman, I. Breikreutz, P. Joosten, C. Scheid, M. van Marwijk-Kooy, H. Salwender, M.H. van Oers, M. Schaafsma, R. Naumann, H. Sinnige, W. Blau, G. Verhoef, O. de Weerd, P. Wijermans, S. Wittebol, U. Duehrsen, E. Vellenga, H. Goldschmidt; for Dutch-Belgian HOVON and German GMMG. Thalidomide in induction treatment increases the very good partial response (VGPR) rate before and after high-dose therapy in previously untreated multiple myeloma. *Haematologica* 93(1):124-127 (2008)  
IF: 5.8
184. Glas M, Hennemann B, Hirschmann B, Marienhagen J, **Schmidt-Wolf** I, Herrlinger U, Bogdahn U, Hau P. Complete response after treatment with a somatostatin analogue in a patient with recurrent medulloblastoma. *Acta Oncologica* 47(3):479-804 (2008)  
IF: 3.0
185. Sievers E, Neuberger J, Starkmuth M, Frank S, Strehl J, **Schmidt-Wolf** IGH. Cytotoxicity of a CD94-enriched fraction from cytokine-induced killer (CIK) cells against tumor cells. *Current Trends in Immunology*, 10:41-48 (2009)  
IF: 0
186. Ines Gütgemann, Kathryn Stevens, David Loftus, Ingo G.H. **Schmidt-Wolf**, Tracy I. George. VEGF and Osteosclerosis in POEMS Syndrome. *Annals Hematol* 87:243-245 (2008)  
IF: 2.6
187. González-Carmona MA, Lukacs-Kornek V, Timmermann A, Shabani S, Kornek M, Vogt A, Yildiz Y, Sievers E, **Schmidt-Wolf** IGH, Caselmann W, Sauerbruch T, Schmitz V. CD40L-expressing DCs induce regression of HCC by activating innate and acquired immunity in vivo. *Hepatology* 48 (1):157-168 (2008)  
IF: 11.1

188. Nagaraj S, Neumann J, Winzen B, Frank S, Ziske C, Sievers E, Koch N, **Schmidt-Wolf IGH**. Pancreas carcinoma antigen fused to invariant chain elicits T cell response and tumor growth inhibition. *Pancreas* 37(3):321-327, 2008  
IF: 3.0
189. Gorschlüter M, Schmitz V, Mey U, Hahn-Ast C, **Schmidt-Wolf IGH**, Sauerbruch T. Endoscopy in patients with acute leukaemia after intensive chemotherapy. *Leukemia Res* 32:1510-1517 (2008)  
IF: 2.4
190. Kim Y, Strehl J, Gorschlüter M, Ziske C, **Schmidt-Wolf IGH**. Prevention of lethal tumor growth and generation of long-lasting immunity in vivo using CD137L and interleukin-12 gene transfer. *In Vivo* 22:337-344 (2008)  
IF: 1.0
191. Gressner O, Popp H, Fmeyer U, Strehl J, Sauerbruch T, **Schmidt-Wolf I**, Gorschlüter M. Long-term survival of a patient with Small Cell Lung Cancer after 9 treatments with different chemotherapy regimens and radiation: a Case Report. *Onkologie* 31:469-472 (2008)  
IF: 0.9
192. Pels H, Juergens A, Glasmacher A, Schulz H, Engert A, Linnebank M, Schackert G, Reichmann H, Kroschinsky F, Vogt-Schaden M, Egerer G, Bode U, Schaller C, Lamprecht M, Hau P, Deckert M, Fimmers R, Bangard C, **Schmidt-Wolf IGH**, Schlegel U. Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study. *J Neurooncol.* 2009 Feb;91(3):299-305.  
IF: 3.1
193. Linnebank M, Moskau S, Jurgens A, Simon M, Semmler A, Orlopp K, Glasmacher A, Bargart C, Vogt-Schaden M, Urbach H, **Schmidt-Wolf IG**, Pels H, Schlegel U. Association of genetic variants of methionine metabolism with MTX-induced CNS white matter changes in patients with primary central nervous system lymphoma. *Neuro Oncol.* 2008 Sep 22.  
IF: 6.8
194. Schmidt M, Sievers E, Endo T, Lu D, Carson D, **Schmidt-Wolf IGH**. Targeting Wnt pathway in lymphoma and myeloma cells. *Brit J Haematol.* 2009 Mar;144(5):796-8.  
IF: 5.0
195. Andrea Linke, Elisabeth Sievers, Maria Gonzalez-Carmona, Carsten Ziske, Davorka Messmer, Volker Schmitz, Tilman Sauerbruch, Peter Brossart, Ingo G. H. **Schmidt-Wolf**. Enhanced inhibition of tumor growth with depletion of CD25 regulatory cells and intratumoral immunization with tumor RNA-pulsed dendritic cells in a C57Bl/6 pancreatic tumor model. *Pancreas* 38 (5):602-604 (2009)  
IF: 3.0
196. Kraemer A, Hauser S, Kim Y, Gorschlüter M, Müller SC, Brossart P, **Schmidt-Wolf I**. Phase I trial of metastatic renal cell carcinoma. with oral capecitabine and thalidomide. *GMS Vol 7*, 2009 (online)  
IF: 0
197. Ziske C, Etzrodt PE, Eliu AS, Gorschlüter M, Strehl J, Flieger D, Messmer D, Schmitz V, Gonzalez-Carmona MA, Sievers E, Brossart P, Sauerbruch T, **Schmidt-Wolf IGH**. Increase of In Vivo Antitumoral Activity by CD40l (CD154) Gene Transfer Into Pancreatic Tumor Cell-Dendritic Cell Hybrids. *Pancreas.* 2009 Oct;38(7):758-65.  
IF: 3.0

198. Juergens A, Pels H, Rogowski S, Fliessbach K, Glasmacher A, Engert A, Reiser M, Diehl V, Vogt-Schaden M, Egerer G, Schackert G, Reichmann H, Kroschinsky F, Bode U, Herrlinger U, Linnebank M, Deckert M, Fimmers R, **Schmidt-Wolf** IGH, Schlegel U. Long-term survival with favorable cognitive outcome after chemotherapy in Primary Central Nervous System Lymphoma. *Ann Neurol* 66:.....(2009)  
IF: 10.0
199. Advani A, Patel H, Boni J, Coiffier B, Czuczman M, Dreyling M, Foran J, Gine E, Gisselbrecht C, Ketterer N, Nasta S, Rohatiner A, **Schmidt-Wolf** IGH, Schuler M, Sierra J, Smith M, Verhoef G, Winter J, Shapiro M, Fayad L. A Phase 1 Study of Inotuzumab Ozogamicin (CMC-544) as Treatment for B-Cell Non-Hodgkin's Lymphoma: *JCO* 28(12):2085-93 (2010); IF 18,4  
IF: 18.4
200. Kim Y, Strehl J, Sievers E, Gorschlüter M, Brossart P, **Schmidt-Wolf** IGH. CD40L transfected myeloma cells transfer prolonged immunity in vivo. *In Vivo* 24:45-48 (2010)  
IF: 1.0
201. Lu D, Liu JX, Endo T, Zhou H, Yao S, Willert K, **Schmidt-Wolf** IGH, Kipps TJ, Carson DA. Ethacrynic acid exhibits selective cytotoxicity to chronic lymphocytic leukemia cells by inhibition of the Wnt/beta-catenin pathway. *PLoS one*, 2009 Dec 14;4(12):e8294  
IF: 3.2
202. Marie von Lilienfeld-Toal, Susanne Frank, Christiane Leyendecker, Sylvia Feyler, Sarah Jarmin, Ruth Morgan, Axel Glasmacher, Angela Märten, Ingo GH **Schmidt-Wolf**, Peter Brossart, Gordon Cook. Reduced immune effector cell NKG2D expression and increased levels of soluble NKG2D ligands in multiple myeloma may not be causally linked. *CII* 2010 Jun;59(6):829-39  
IF: 3.9
203. Hendrik Pels\*, Annika Juergens\*, Isabell Schirgens, Axel Glasmacher, Holger Schulz, Andreas Engert, Gabriele Schackert, Heinz Reichmann, Frank Kroschinsky, Marlies Vogt-Schaden, Gerlinde Egerer, Udo Bode, Martina Deckert, Rolf Fimmers, Horst Urbach, Ingo G.H. **Schmidt-Wolf**, Uwe Schlegel. Early complete response during chemotherapy predicts favourable outcome in patients with primary CNS lymphoma. *Neurooncology*, 2010 Jul;12(7):720-4, Epub 2010 Feb 16  
IF: 6.8
204. Kraemer M, Hauser S, **Schmidt-Wolf** I. Long-term survival of patients with metastatic renal cell carcinoma treated with pulsed dendritic cells. *Anticancer Res.* 2010 Jun;30(6):2081-6.  
IF: 1.8
205. Sven Simons, Susanne Ringsdorf, Michael Braun, Ulrich JM Mey, Yon D Ko, Walther Kuhn, Ingo **Schmidt-Wolf**, Peter F Schwindt, Ulrich Jaehde. Enhancing adherence to capecitabine chemotherapy by means of pharmaceutical care: a prospective observational cohort study, *Supportive Care in Cancer.* IF(2010):2,1 (2011) 19:1009-1018, published online 16 June 2010  
IF: 2.4
206. B. Busert, G. Schwanitz, R. Schubert, U. Gamedinger, I.G.H **Schmidt-Wolf**. Characterization of the karyotype in patients with multiple myeloma by the combination of karyotype analysis, FISH and CGH. *Int J Human Genetics*, 2011. IF(2010):0,2, (2010)10(4):217-222  
IF: 0.4
207. Sievers E, Neuberg J, Starkmuth M, Frank S, Strehl J, **Schmidt-Wolf** IGH. Cytotoxicity of a CD94-enriched fraction from cytokine-induced killer (CIK) cells against tumor cells. *Current Trends in Immunology*, 10:41-48 (2009)

IF: 0

208. Pels H, Juergens A, Glasmacher A, Schulz H, Engert A, Linnebank M, Schackert G, Reichmann H, Kroschinsky F, Vogt-Schaden M, Egerer G, Bode U, Schaller C, Lamprecht M, Hau P, Deckert M, Fimmers R, Bangard C, **Schmidt-Wolf** IGH, Schlegel U. Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study. *J Neurooncol.* 2009 Feb;91(3):299-305.

IF: 3.1

209. Linnebank M, Moskau S, Jurgens A, Simon M, Semmler A, Orlopp K, Glasmacher A, Bargart C, Vogt-Schaden M, Urbach H, **Schmidt-Wolf** IG, Pels H, Schlegel U. Association of genetic variants of methionine metabolism with MTX-induced CNS white matter changes in patients with primary central nervous system lymphoma. *Neuro Oncol.* 2008 Sep 22.

IF: 6.8

210. Schmidt M, Sievers E, Endo T, Lu D, Carson D, **Schmidt-Wolf** IGH. Targeting Wnt pathway in lymphoma and myeloma cells. *Brit J Haematol.* 2009 Mar;144(5):796-8.

IF: 5.0

211. Andrea Linke, Elisabeth Sievers, Maria Gonzalez-Carmona, Carsten Ziske, Davorka Messmer, Volker Schmitz, Tilman Sauerbruch, Peter Brossart, Ingo G. H. **Schmidt-Wolf**. Enhanced inhibition of tumor growth with depletion of CD25 regulatory cells and intratumoral immunization with tumor RNA-pulsed dendritic cells in a C57Bl/6 pancreatic tumor model. *Pancreas* 38 (5):602-604 (2009)

IF: 3.0

212. Kraemer A, Hauser S, Kim Y, Gorschlüter M, Müller SC, Brossart P, **Schmidt-Wolf** I. Phase I trial of metastatic renal cell carcinoma. with oral capecitabine and thalidomide. *GMS Vol 7*, 2009 (online)

IF: 0

213. Ziske C, Etzrodt PE, Eliu AS, Gorschlüter M, Strehl J, Flieger D, Messmer D, Schmitz V, Gonzalez-Carmona MA, Sievers E, Brossart P, Sauerbruch T, **Schmidt-Wolf** IGH. Increase of In Vivo Antitumoral Activity by CD40L (CD154) Gene Transfer Into Pancreatic Tumor Cell-Dendritic Cell Hybrids. *Pancreas.* 2009 Oct;38(7):758-65.

IF: 3.0

214. Juergens A, Pels H, Rogowski S, Fliessbach K, Glasmacher A, Engert A, Reiser M, Diehl V, Vogt-Schaden M, Egerer G, Schackert G, Reichmann H, Kroschinsky F, Bode U, Herrlinger U, Linnebank M, Deckert M, Fimmers R, **Schmidt-Wolf** IGH, Schlegel U. Long-term survival with favorable cognitive outcome after chemotherapy in Primary Central Nervous System Lymphoma. *Ann Neurol* 66:.....(2009)

IF: 10.0

215. Kim Y, Strehl J, Sievers E, Gorschlüter M, Brossart P, **Schmidt-Wolf** IGH. CD40L transfected myeloma cells transfer prolonged immunity in vivo. *In Vivo* 24:45-48 (2010)

IF: 1.0

216. Stefan Gröschel<sup>1\*</sup>, Sanne Lugthart<sup>2\*</sup>, Richard F. Schlenk<sup>1</sup>, Peter J.M. Valk<sup>2</sup>, Karina Eiwien<sup>1</sup>, Chantal Goudswaard<sup>2</sup>, Wim J.L. van Putten<sup>3</sup>, Sabine Kayser<sup>1</sup>, Leo Verdonck<sup>4,5</sup>, Michael Lübbert<sup>6</sup>, Gert-Jan Ossenkoppele<sup>7</sup>, Ulrich Germing<sup>8</sup>, Ingo **Schmidt-Wolf**<sup>9</sup>, Brigitte Schlegelberger<sup>10</sup>, Jürgen Krauter<sup>11</sup>, Arnold Ganser<sup>11</sup>, Hartmut Döhner<sup>1</sup>, Bob Löwenberg<sup>2</sup>, Konstanze Döhner<sup>1\*</sup>, and Ruud Delwel. High *EVII* Expression Predicts Outcome in Younger Adult Patients with Acute Myeloid Leukemia and Is Associated with Distinct Cytogenetic Abnormalities. *J Clin Oncol.* 2010 Apr 20;28(12):2101-7.

IF: 18.4

217. Lu D, Liu JX, Endo T, Zhou H, Yao S, Willert K, **Schmidt-Wolf** IGH, Kipps TJ, Carson DA. Ethacrynic acid exhibits selective cytotoxicity to chronic lymphocytic leukemia cells by inhibition of the Wnt/beta-catenin pathway. *PLoS one*, 2009 Dec 14;4(12):e8294  
IF: 3.2
218. Marie von Lilienfeld-Toal, Susanne Frank, Christiane Leyendecker, Sylvia Feyler, Sarah Jarmin, Ruth Morgan, Axel Glasmacher, Angela Märten, Ingo GH **Schmidt-Wolf**, Peter Brossart, Gordon Cook.. Reduced immune effector cell NKG2D expression and increased levels of soluble NKG2D ligands in multiple myeloma may not be causally linked. *CII* 19. Dec 2009 online  
IF: 3.9
219. Hendrik Pels\*, Annika Juergens\*, Isabell Schirgens, Axel Glasmacher, Holger Schulz, Andreas Engert, Gabriele Schackert, Heinz Reichmann, Frank Kroschinsky, Marlies Vogt-Schaden, Gerlinde Egerer, Udo Bode, Martina Deckert, Rolf Fimmers, Horst Urbach, Ingo G.H. **Schmidt-Wolf**, Uwe Schlegel. Early complete response during chemotherapy predicts favourable outcome in patients with primary CNS lymphoma. *Neurooncology*, 2010 Jul;12(7):720-4, Epub 2010 Feb 16  
IF: 6.8
220. Kraemer M, Hauser S, **Schmidt-Wolf** I. Long-term survival of patients with metastatic renal cell carcinoma treated with pulsed dendritic cells. *Anticancer Res.* 2010 Jun;30(6):2081-6.  
IF: 1.8
221. Hontscha C, Zhou H, Negrin R, **Schmidt-Wolf** IGH. Clinical trials on CIK cells: First report of the international registry on CIK cells (IRCC). *J Cancer Res Clin Oncol*, 2011 Feb;137 (2):305-310.  
IF: 3.1
222. Sven Simons, Susanne Ringsdorf, Michael Braun, Ulrich JM Mey, Yon D Ko, Walther Kuhn, Ingo **Schmidt-Wolf**, Peter F Schwindt, Ulrich Jaehde. Enhancing adherence to capecitabine chemotherapy by means of pharmaceutical care: a prospective observational cohort study, *Supportive Care in Cancer*. IF(2010):2,1 (2011) 19:1009-1018, published online 16 June 2010  
IF: 2.4
223. B. Busert, G. Schwanitz, R. Schubert, U. Gamberdinger, I.G.H **Schmidt-Wolf**. Characterization of the karyotype in patients with multiple myeloma by the combination of karyotype analysis, FISH and CGH. , *Int J Human Genetics*, 2011. IF(2010):0,2, (2010)10(4):217-222  
IF: 0.4
224. Schmidt M, Sievers E, Endo T, Lu D, Glasmacher A, Brossart P, Carson D, **Schmidt-Wolf** IGH Increased efficacy of lenalidomide and thalidomide by addition of PO targeting the Wnt pathway. *In Vivo* 25 (1):99-103 IF(2010): 1,2  
IF: 1.0
225. Nowak M, Arredouani M, Tun-Kyi A, **Schmidt-Wolf** IGH, Sanda M, Balk S, Exley M. Defective NKT cell activation by CD1d+ TRAMP prostate tumor cells is corrected by interleukin-12 with alpha-galactosylceramide. *PLoS One*. 2010 Jun 25;5(6):e11311. IF(2010):4,4  
IF: 3.2
226. Gaidzik V, Bullinger L, Schlenk R, Zimmermann A, Röck J, Paschka P, Corbacioglu A, Krauter J, Schlegelberger B, Ganser A, Späth D, Germing U, **Schmidt-Wolf** IGH, Götze K, Nachbaur D, Pfreundschuh M, Horst H, Döhner H, Döhner K. *RUNX1* mutations in acute myeloid leukemia – a distinct biological subgroup associated with inferior outcome. Results of the AML Study Group (AMLSSG). *JCO*, Volume 29 (2011);

- IF: 18.4
227. Schmidt M, Sievers E, Endo T, Lu D, Glasmacher A, Brossart P, Carson D, **Schmidt-Wolf** IGH Increased efficacy of lenalidomide and thalidomide by addition of griseofulvin targeting the Wnt pathway. *Leuk Res.* 35(8):1070-3. IF(2011):2,6  
IF: 2.4
228. Yang Li<sup>1,2</sup>, Yan-feng Wu<sup>2</sup>, Ingo GH **Schmidt-Wolf**<sup>3</sup>, Shao-liang Huang<sup>1</sup>, Hai-xia Guo<sup>1</sup>, Jianpei Fang<sup>1</sup>, Jing Wei<sup>4</sup>, Ke Huang<sup>1</sup>, Dun-hua Zhou<sup>1</sup>. Optimized protocols for generation of cord blood derived cytokine-induced killer / natural killer cells. *Anticancer Res.* Sept 30(9):3493-3499 (2010).  
IF: 1.8
229. Young Kim, Guido Reifenberger, Desheng Lu, Tomoyuki Endo, Dennis A Carson, Sanna-Marie Gast, Karoline Meschenmoser, Michael Nowak, Ingo G. H. **Schmidt-Wolf**. Influencing the Wnt Signaling Pathway in Multiple Myeloma. *Anticancer Res.* IF(2010):1,7, 2011; Volume 31; Issue 2, Pages 725-730  
IF: 1.8
230. Schmidt M, Kim Y, Gast S-M, Endo T, Lu D, Carson D, Kipps T, **Schmidt-Wolf** IGH Increased in vivo efficacy of lenalidomide and thalidomide by addition of ethacrynic acid., *In Vivo.* IF(2010):1,2, 2011 May- June; 25 (3):325-33  
IF: 1.0
231. Ingo G.H. **Schmidt-Wolf** (1), Hendrik Pels (2), Annika Jürgens (2), Katrin Patrij (1), Luise Wätzel (3), Ulrich Herrlinger (1), Holger Schulz (3), Andreas Engert (3), Michael Linnebank (1), Gabriele Schackert (4), Heinz Reichmann (4), Frank Kroschinsky (4), Marlies Vogt-Schaden (5), Gertlinde Egerer (5), Carlo Schaller (3), Monika Lamprecht (6), Peter Hau (7), Martina Deckert (3), Rolf Fimmers (1), Christoph Bangard (3), Marcel Reiser (3). Relapse of central nervous system lymphoma (CNSL) AFTER SYSTEMIC LYMPHOMA (SCNSL): Clinical features and outcome AS COMPARED TO PRIMARY CNS LYMPHOMA (PcnsL) PATIENTS. *GMS*, May 2; 2011  
IF: 0
232. Thanandarajan S, Nowak M, Abken H, **Schmidt-Wolf** IGH. Combining cytokine-induced killer cells with vaccination in cancer immunotherapy: More than one plus one? *Leukemia Res.* <http://dx.doi.org/10.1016/j.leukres.2011.05.005>. IF(2010):2,6, 2011 Sept; 35 (9): 1136-42  
IF: 2.4
233. Schöttker B, Märten A, Kenn C, Ziske C, Renoth S, Buttgereit P, Schakowski F, Gorschlüter M, **Schmidt-Wolf** IGH. Dendritic Cells Enhance the Anti-Leukemic Activity of Cytokine-Induced Killer Cells against Allogeneic Acute Myelogenous Leukaemia Cells. *GMS* unter <http://www.egms.de/en/journals/gms/2011-9/000141.shtml>, August 4; 2011  
IF: 0
234. Auel, Britta (1), Goldschmidt, Hartmut (2), Geer, Thomas (3), Moehler Thomas M (2), Platzbecker, Uwe (4), Naumann, Ralph (4), Blau, Igor (5), Hänel, Mathias (6), Knauf, Wolfgang (7), Nüchel, Holger (8), Salwender, Hans-Jürgen (9), Scheid, Christof (10), Weisel, Katja (11), Gorschlüter, Marcus (1), Glasmacher, Axel (1), **Schmidt-Wolf**, Ingo GH (1), for the German Refractory Myeloma Study Group. Treatment with thalidomide and cyclophosphamide (TCID) is superior to vincristine (VID) and to vinorelbine (VRID) regimens in patients with refractory or recurrent multiple myeloma. *Ind J Hematol*, DOI 10.1007/s12288-011-0133-1; 2012 IF 0.3
235. Schmidt M, Sievers E, Endo T, Lu D, Glasmacher A, Brossart P, Carson D, Kipps T, **Schmidt-Wolf** IGH Increased efficacy of lenalidomide and thalidomide by addition of cic targeting the Wnt pathway. *In Vivo*, Nov-Dec; 25(6):887-93. IF(2011):1,2

- IF: 1.0
236. Futralan D, Huang CT, **Schmidt-Wolf I**, Larsson M, Messmer D. Effect on oxygen levels on the physiology of dendritic cells: Implications for adoptive cell therapy. *Molecular Medicine*, IF(2010):5,9, 2011; Sept-Oct 17 (9-10): 910-6  
IF: 4.5
237. Hendrayana T, Kurth V, Krolop L, Kenny P, Hilger RA, **Schmidt-Wolf IGH**, Ko YD, Jaehde U. Variability in fluorouracil exposure during continuous intravenous infusion. *International Journal of Clinical Pharmacology and Therapeutics*, IF(2010):1,2, 2012 Jan 50 (1):82-4  
IF: 1.2
238. Nowak, **Schmidt-Wolf**. Natural Killer T Cells Subsets in Cancer, Functional Defects in Prostate Cancer and Implications for Immunotherapy. *Cancers*, 2011; 3(3):3661-3675  
IF: 5.2
239. Schwamborn, Katharina, Gorschlüter, Marcus, Glasmacher, Axel, **Schmidt-Wolf**, Ingo GH for the German Refractory Myeloma Study Group. Efficacy of dose-reduced lenalidomide in patients with refractory or recurrent multiple myeloma. *GMS*, September 27;2011  
IF: 0
240. Stuplich, **Schmidt-Wolf**, Herrlinger. Case report of a patient with Richter syndrome. *Acta Haematologica*, (IF1,3), 2011 Dec 10;127(2):93-95  
IF: 1.1
241. Thanendrarajan S, Kim Y, **Schmidt-Wolf IGH**. Understanding and targeting the Wnt/ $\beta$ -catenin signaling pathway in chronic leukemia. *Leukemia Research and Treatment*, vol. 2011, <http://www.hindawi.com/journals/lrt/2011/329572/> (IF-), 14 Oct 2011: Pages 1-7  
IF: 0
242. Kim Y, Thanendrarajan S, **Schmidt-Wolf IGH**. Wnt/ $\beta$ -Catenin: a new therapeutic Approach to Acute Myeloid Leukemia? *Leukemia Research and Treatment*, vol. 2011, <http://www.hindawi.com/journals/lrt/2011/428960/> (IF-); 21 Oct 2011: Pages 1-4  
IF: 0
243. Schlimper C, Hombach A, Abken H, **Schmidt-Wolf IGH**. T Cells and NKT cells Grafted with Recombinant Immunoreceptor against autologous Primary Colorectal Carcinoma Cells. *Clinical and Developmental Immunology* 2012:238924 (IF2,3)  
IF: 2.9
244. Volker Kunzmann, Manfred Smetak, Brigitte Kimmel, Karin Weigang-Koehler, Mariele Goebeler, Josef Birkmann, Jürgen Becker, Ingo G. H. **Schmidt-Wolf**, Hermann Einsele, Martin Wilhelm. Phase II Trial of Zoledronic Acid plus Interleukin-2 in Patients with Solid and Hematological Malignancies. *JIT* (IF3,8), 2012 Feb;35(2):205-13  
IF: 0.6
245. Koppitz H, **Schmidt-Wolf IGH**, Rockstroh JK, Schüller H, Standop J, Skowasch D, Müller-Hermelink HK, **Schmidt-Wolf IGH**. Current status of classification and multimodality treatment of malignant thymoma: An update. *Cancer Treatment Reviews*, <http://dx.doi.org/10.1016/j.ctrv.2011.11.010> (IF7,6), online 13 January 2012  
IF: 7.6
246. Linnebank M, Moskau S, Kowoll A, Semmler A, Bangard C, Vogt-Schaden M, Egerer G, Schackert G, Reichmann H, **Schmidt-Wolf IG**, Pels H, Schlegel U. Association of transcobalamin c. 776C>G with overall survival in patients with primary central nervous system lymphoma. *Br J Cancer*. 2012 Nov 20;107(11):1840-3. doi: 10.1038/bjc.2012.476. 2012. (IF5,0)  
IF: 4.8

247. Kai Neben, Henk M Lokhorst, Anna Jauch, Uta Bertsch, Thomas Hielscher, Bronno van der Holt, Dirk Hose, Stefan Schmitt, Laila el Jarari, Hans Salwender, Igor Wolfgang Blau, Michael Pfreundschuh, Katja Weisel, Ulrich Dührsen, Walter Lindemann, Christian Teschendorf, Hans Martin, Christof Scheid, Mathias Haenel, Hans Guenter Derigs, Ullrich Graeven, Ingo G. H. **Schmidt-Wolf**, Norma Peter, Mohammed Wattad, Jörg Schubert, Martin Hoffmann, Martin Goerner, Jochen Tischler, Martin Kaufmann, Helgi van de Velde, Marc S Raab, Pieter Sonneveld, Hartmut Goldschmidt. Administration of bortezomib before and after autologous stem-cell transplantation improves outcome in Multiple Myeloma patients with deletion 17p – a Subgroup Analysis of the HOVON/GMMG-HD4 Trial. *Blood*, (IF 10,6), January 26;2012 Vol 119;no 4:940-948  
IF: 10.5
248. Jäckel C, Meschenmoser K, Kim Y, Weiher, **Schmidt-Wolf** IGH. Efficacy of a proapoptotic peptide in breast cancer cells. *In Vivo* 2012 May-Jun;26(3):419-26. IF(2010):1,2  
IF: 1.0
249. Young Kim, Sanna-Marie Gast, Tomoyuki Endo, Desheng Lu, Dennis Carson, Ingo G.H. **Schmidt-Wolf** *In vivo* efficacy of the diuretic agent ethacrynic acid against multiple myeloma. *Leukemia Research*. 36(5):598-600 (2012). IF 2,6  
IF: 2.4
250. Thanendrarajan S, Kim Y, **Schmidt-Wolf** IGH. New adoptive immunotherapy strategy for solid tumors with CIK cells. *Expert Opin Biol Ther*. 2012 May;12(5):565-72. IF 3,3  
IF: 3.7
251. Sonneveld P, **Schmidt-Wolf** IGH, van der Holt B, el Jarari L, Bertsch U, Salwender H, Zweegman S, Vellenga E, Broyl A, Blau IW, Weisel K, Wittebol S, Bos GMJ, Stevens-Kroef M, Scheid C, Pfreundschuh M, Hose D, Jauch A, van de Velde H, Raymakers R, Schaafsma MR, Kersten MJ, van Marwijk Kooy M, Dührsen U, Lindemann W, Wijermans PW, Lokhorst HM, Goldschmidt H. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase 3 HOVON-65/GMMG-HD4 trial. *J Clin Oncol*. 2012 Aug 20;30(24):2946-55. IF(2010):19,0  
IF: 18.4
252. Gröschel S, Schlenk R, Engelmann J, Rockova V, Teleanu V, Kühn M, Eiwen K, Erpelinck C, Havermans M, Lübbert M, Germing U, **Schmidt-Wolf** IGH, Beverloo B, Schlegelberger B, Krauter J, Ganser A, Valk P, Löwenberg B, Döhner K, Döhner H, Delwel R. Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian AMLSG and Dutch-Belgian HOVON groups. *J Clin Oncol* 31(1):95-103 (2013);  
IF: 18.4
253. Yordanova, Anna (1), Hose, D (2), Neben, K (2), Witzens-Harig, M (2), Klein, B (2), Moehler, T (2), Goldschmidt, Hartmut (2), **Schmidt-Wolf**, Ingo GH. Efficacy of sorafenib in patients with refractory or recurrent multiple myeloma. *Hematological Oncology*, *Hematol Oncol*. 2013 Mar 15. doi: 10.1002/hon.2043. [Epub ahead of print].  
IF: 3.1
254. F. McClanahan<sup>1</sup>, T. Hielscher<sup>2</sup>, M. Rieger<sup>1</sup>, M. Hensel<sup>3</sup>, M. Bentz<sup>4</sup>, I. **Schmidt-Wolf**<sup>5</sup>, A. Käbisch<sup>6</sup>, H. Salwender<sup>7</sup>, H. Dürk<sup>8</sup>, H. Staiger<sup>9</sup>, T. Mandel<sup>10</sup>, K. Neben<sup>1</sup>, J. Hillengass<sup>1</sup>, A.D. Ho<sup>1</sup>, M. Witzens-Harig<sup>1</sup>. Final results of a prospective, multicentre, randomized trial comparing 1, 3 or 6 infusions of Rituximab combined with 6 cycles of CHOP chemotherapy in untreated patients with advanced follicular lymphoma (HD2000 trial). *Am J Hematol* 2012 Oct;87(10):E68-71.



- IF: 3.8
255. Markus Chmielewski<sup>1</sup>, Olga Hahn<sup>1</sup>, Michael Nowak<sup>2</sup>, Ingo H. **Schmidt-Wolf**<sup>2</sup>, Andreas A. Hombach<sup>1</sup> and Hinrich Abken<sup>1</sup>. Regression of pancreatic carcinoma without inducing auto-immune colitis by T cell therapy targeting carcinoembryonic antigen. *Gastroenterology*. 2012 Oct;143(4):1095-107.  
IF: 16.7
256. Low HZ, Kramer D, **Schmidt-Wolf** IGH, Illges H. Shedding of CD21 is enhanced and correlates with attenuated surface expression of CD21 in CLL but not in MM. *International Journal of Hematology*, 2012 Sep;96(3):350-6.  
IF: 1.9
257. Jäkel C, Hauser S, Rogenhofer S, Müller SC, Brossart P, **Schmidt-Wolf** IGH. Clinical studies applying cytokine-induced killer cells for the treatment of renal cell carcinoma. *Clinical and Developmental Immunology* vol. 2012, Article ID 473245, 7 pages, 2012. doi:10.1155/2012/473245.  
IF: 2.9
258. Khristi J, Gütgemann I, **Schmidt-Wolf** I. Composite lymphoma: case reports and review of the literature. *Annals Hematol*, 2013 Apr 5. [Epub ahead of print].  
IF: 2.6
259. Koller CM, Kim Y, **Schmidt-Wolf** IGH. Targeting renal cancer with a combination of WNT inhibitors and a bi-functional peptide. *Anticancer Res*. 2013 Jun;33(6):2435-40.  
IF: 1.8
260. Meschenmoser K, Messmer D, **Schmidt-Wolf** IGH. Peptide inhibition in breast cancer. *In Vivo*, 2013 Jul-Aug;27(4):431-42.  
IF: 1.0
261. Saineb Al Mansoor, Ziske C, **Schmidt-Wolf** IGH. Primary small-cell carcinoma of the esophagus: Multivariate analysis and review of the literature. *Ger Med Sci*. 2013 Aug 23;11:Doc12. doi: 10.3205/000180.  
IF: 0
262. Michael Nowak, Benjamin Krämer, Manuela Haupt, Panos Papapanou, J. Kebschull, P. Hoffmann, **Schmidt-Wolf** IGH, Sören Jepsen, Peter Brossart, S Perner, Moritz Kebschull. Activation of Invariant Natural Killer T cells in Periodontitis Lesions. *J Immunol* 2013; 190(5): 2282-91 (2013)  
IF: 4.9
263. Vogt A, Sievers E, Lukacs-Kornek V, Decker G, Raskopf E, Meumann N, Büning H, Sauerbruch T, Strassburg CP and **Schmidt-Wolf** and Gonzalez-Carmona MA. Improving immunotherapy of hepatocellular carcinoma (HCC) using dendritic cells (DC) engineered to express IL-12 *in vivo*. 2013, *Liver International*, im Druck  
IF: 4.9
264. Schmeel ....wnt and piceatannol..... *Anticancer Res*, in Druck  
IF: 1.8
265. Christof Scheid<sup>1\*</sup>, Pieter Sonneveld<sup>2</sup>, Ingo G.H. **Schmidt-Wolf**<sup>3\*</sup>, Bronno van der Holt<sup>2\*</sup>, Thomas Hielscher<sup>4\*</sup>, Laila el Jarari<sup>2\*</sup>, Uta Bertsch<sup>5\*</sup>, Hans Salwender<sup>3\*</sup>, Sonja Zweegman<sup>2\*</sup>, Igor Wolfgang Blau<sup>3\*</sup>, Edo Vellenga<sup>2</sup>, Katja Weisel<sup>3\*</sup>, Michael Pfreundschuh<sup>3\*</sup>, Asiong Jie<sup>2\*</sup>, Helgi van de Velde<sup>6\*</sup>, Ulrich Dührsen<sup>3</sup>, Martijn Schaafsma<sup>2\*</sup>, Walter Lindemann<sup>3\*</sup>, Marie Jose Kersten<sup>2\*</sup>, Norma Peter<sup>3\*</sup>, Michel Delforge<sup>7</sup>, Mathias Hänel<sup>3</sup>, Sandra Croockewit<sup>2\*</sup>, Hans Martin<sup>3\*</sup>, Shulamit Wittebol<sup>2\*</sup>, Harry Schouten<sup>2</sup>, Marinus van Marwijk-Kooy<sup>2\*</sup>, Pierre Wijermans<sup>2\*</sup>, Henk M Lokhorst<sup>2\*</sup> and Hartmut Goldschmidt<sup>5</sup>. Bortezomib as induction and maintenance treatment before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment: A Subgroup Analysis From the HOVON-65/GMMG-HD4

Randomized Phase III Trial for Newly Diagnosed Multiple Myeloma. *Haematologica*, in Druck

IF: 5.8

266. Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balsler C, Kaiser U, Weidmann E, Dürk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W; Study group indolent Lymphomas (StiL). Rummel M, Kaiser U, Niederle N, Link H, Brugger W, Barth J, Welslau M, Banat A, Hinke A, Knauf W, Kofahl-Krause D, Weidmann E, Klein M, Baldus M, Sandherr M, Aulmann C, Schlimok G, Baldus M, Böck HP, Balló H, Balsler C, Weidenbach F, Behringer D, Krüger S, Mitrou PS, Bojko P, Abenhardt W, Breuer F, Brudler O, Brugger W, Burchardt A, Blau W, Banat A, Chow K, Cordes HJ, Clemens M, Mahlberg R, Dürk H, Eckart M, Eggert J, Fiechtner H, Fuxius S, Görner M, Just M, Schäfer E, Graubner M, Günther G, Hahn L, Hecker R, Heil G, Herrmann O, Hochdörfer S, Hoffmann T, Hünermund K, Immenschuh P, Burk M, Josten K, Kaiser U, Heide T, Katz F, Klein S, Knauf W, Tesch H, Kobbe G, Zohren F, Haas R, Koch M, Rauh J, Köchling G, Kofahl-Krause D, Ganser A, Kojouharoff G, Dingeldey G, Koniczek S, Link H, Kirsch J, Losem C, Maschmeyer G, Rothmann F, Matzdorff A, Mittermüller J, Müller S, Hahn M, Müller L, Müller-Hagen S, Neise M, Schalk K, Neuhaus T, Hens K, Niederle N, Heider A, Kloster G, Nowak H, Prümmer O, Reeb M, Hansen R, Rohrberg R, Hurtz HJ, Fritze D, Rost A, Brecht A, Kayser R, Bernhard H, Sandherr M, Perker M, Schauer M, Schlag R, Schliesser G, Käbisch A, Weber C, Schmidt UM, **Schmidt-Wolf I**, Brossart P, Schneider J, Schröder J, Schroeder M, Schütte HJ, Artmann KD, Schwaner I, Seipelt G, Koch U, Selbach J, Anhuf J, Söling U, Stauch M, Thiel E, Hofmann WK, Fischer L, Tischbirek K, von Grünhagen U, Wagner H, Wilke J, Wattad M, Reimer P, Weide R, Heymanns J, Weidmann E, Jäger E, Weiss J, Welslau M, Klausmann M, Wittmann G, Zimmer J. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. *Lancet*. 2013 Apr 6;381(9873):1203-10.

IF: 45.2

267. Schmeel FC, Schmeel LC, Kim Y, **Schmidt-Wolf IGH**. Piceatannol exhibits selective toxicity to multiple myeloma cells and influences the Wnt/ beta-catenin pathway.

*Hematol Oncol*. 2014 Dec;32(4):197-204.

IF: 4.8

268. Gast SM, **Schmidt-Wolf IGH**. Wnt pathway in lymphoma and myeloma. Review. *Drugs of the Future* (e-mail von Lücker). In Druck.

IF: 0.2

269. Clara Jäkel, Annabelle Vogt, Maria Gonzalez-Carmona and Ingo G.H. **Schmidt-Wolf**.

Clinical Studies Applying Cytokine-Induced Killer Cells for the Treatment of Gastrointestinal Tumors. *Journal of Immunology Research* (formerly *Clinical & Developmental Immunology*) vol. 2014, Article ID 897214, 12 pages, 2014.

doi:10.1155/2014/897214.

IF: Not Available

270. Maevis, Mey U, **Schmidt-Wolf G**, **Schmidt-Wolf IGH**. Recent advances in the pathophysiology and treatment of hairy cell leukemia. *Blood Cancer Journal*, in Druck.

IF: 3.5

271. H. Goldschmidt, · M.-S. Raab, · K. Neben, · K. Weisel, · I. **Schmidt-Wolf**. Strategien beim rezidivierten/refraktären multiplen Myelom. *Der Onkologe* 3/2014, in Druck.

IF: 0.1

272. Jäkel C, **Schmidt-Wolf** IGH. New adoptive immunotherapy strategy for solid tumors with CIK cells. *Expert Opin Biol Ther*.  
<http://informahealthcare.com/eprint/nvPMZzUmUDmXmUXB7KRH/full>.  
 IF: 3.7
273. **Schmidt-Wolf** I. Rezidivtherapie beim Multiplen Myelom. *Journal Onkologie*, 116-120, 2/2014  
 IF: 0.9
274. **Schmidt-Wolf** IGH, Straka C, Scheid C, Einsele H, Goldschmidt H, Engelhardt M. Behandlung des rezidivierten oder refraktären Multiplen Myeloms. *DMW* 41:2091-2095 (2014)  
 IF: 0.5
275. Von Schulz-Hausmann S, Schmeel LC, Schmeel FC, **Schmidt-Wolf** IGH. Targeting the wnt/beta-catenin pathway in RCC. *Anticancer Res*, in Druck  
 IF: 1.8
276. Wall I, **Schmidt-Wolf** IGH. Effect of wnt inhibitors in pancreatic cancer. Ursprünglich geplant *Gastroenterology* (bereits formatiert) IF 12,8; in Druck, *Anticancer Res*  
 IF: 1.8
277. Schmeel FC, Schmeel LC, Gast SM, **Schmidt-Wolf** IGH. Adoptive immunotherapy strategies with CIK cells in the treatment of hematological malignancies. *Int. J. Mol. Sci.* 2014, 15, 14632-14648; doi:10.3390/ijms150814632  
 IF: 2.9
278. André Wilmer<sup>1</sup>, Corinna Jansen<sup>1</sup>, Yon-Dschun Ko<sup>2</sup>, Ingo **Schmidt-Wolf**<sup>3</sup> und Ulrich Jaehde<sup>1</sup>. Multiprofessionelles Medikationsmanagement bei Krebspatienten. *Forum* 29:324-330. 2014  
 IF: 0
279. Dieter Hoelzer<sup>1</sup>, Jan Walewski<sup>2</sup>, Hartmut Döhner<sup>3</sup>, Andreas Viardot<sup>3</sup>, Wolfgang Hiddemann<sup>4</sup>, Anja Baumann<sup>4</sup>, Hubert Serve<sup>1</sup>, Ulrich Dührsen<sup>5</sup>, Andreas Hüttmann<sup>5</sup>, Eckhard Thiel<sup>6</sup>, Jolanta Dengler<sup>7</sup>, Michael Kneba<sup>8</sup>, Markus Schaich<sup>9</sup>, Ingo G. H. **Schmidt-Wolf**<sup>10</sup>, Joachim Beck<sup>11</sup>, Bernd Hertenstein<sup>12</sup>, Albrecht Reichle<sup>13</sup>, Katarzyna Domanska-Czyz<sup>2</sup>, Rainer Fietkau<sup>14</sup>, Heinz-August Horst<sup>15</sup>, Harald Rieder<sup>16</sup>, Stefan Schwartz<sup>6</sup>, Thomas Burmeister<sup>6</sup> and Nicola Gökbuget<sup>1</sup>. Improved Outcome of Adult Burkitt Non-Hodgkin Lymphoma and Leukemia Patients with Rituximab and a Short-Intensive Chemotherapy; Report of a Large Prospective Multicenter Trial. *Blood*, in Druck  
 IF: 10.5
280. Leonard Christopher Schmeel<sup>1, \*</sup>, Frederic Carsten Schmeel<sup>1, \*</sup>, Young Kim<sup>1</sup>, Sabine Blaum-Feder<sup>1</sup>, Tomoyuki Endo<sup>2</sup> and Ingo G.H. **Schmidt-Wolf**<sup>1</sup> In vitro efficacy of cinnarizine against lymphoma and multiple myeloma. *Anticancer Res*, in Druck  
 IF: 1.8
281. Proetel U, Pletsch N, Lauseker M, Müller MC, Hanfstein B, Krause SW, Kalmanti L, Schreiber A, Heim D, Baerlocher GM, Hofmann WK, Lange E, Einsele H, Wernli M, Kremers S, Schlag R, Müller L, Hänel M, Link H, Hertenstein B, Pffirman M, Hochhaus A, Hasford J, Hehlmann R, Sauße S; German Chronic Myeloid Leukemia Study Group; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK). Wernli M, Bargetzi M, Fischer von Weikersthal L, Groß V, Müller S, Hahn M, Schlimok G, Reichert D, Janssen J, Furkert J, Mandel T, Majunke PJ, Paliege R, Reichert P, Fuss H, Neben K, Staiger HJ, Heim D, Gratwohl A, Tichelli A, Korsten S, Henesser D, Le Coutre P, Arnold R, Ludwig WD, Ratei R, Teutsch C, Ludwig F, Urmersbach A, Blau I, Ihle H, Sperling C, Schelenz C, Koschuth A, Kingreen D, Heßling J, Derwahl KM, Oldenkott B, Englisch HJ, Ludwig F, Thiel E, Burmeister T, Notter M, de Wit M, Rothaug W, Büschel

G, Beyer J, Dahmen E, Biaggi C, Lämmle B, Friess D, Baerlocher G, Oppliger Leibundgut E, Tobler A, Just M, Schäfer E, Behringer D, Brandt M, Schmiegel W, Vaupel HA, Verbeek W, Ko YD, Weidenhöfer S, Sauerbruch T, Hahn-Ast C, Janzen V, Schmidt-Wolf I, Trenn G, van der Linde M, Pommerien W, Fritz L, Krauter J, Lordick F, Fritsch G, Pflüger KH, Diekmann C, Kullmer J, Doering G, Munzinger H, Hertenstein B, Peyn A, Mayer J, Záčková D, Kujickova J, Stier S, Wejda B, Möller-Faßbender F, Hänel M, Morgner A, Herbst R, Matek W, Lamberti C, Zöllner T, Koch B, Marth T, Henzel A, Wagner S, Woska E, Neumann F, Hoffknecht MM, Illmer T, Wolf T, Ehninger G, Kiani A, Platzbecker U, Aul C, Badrakhan CD, Giagounidis A, Flaßhove M, Henneke F, Moritz T, Simon M, Müller LL, Janz R, Eckart M, Häcker B, Rech D, Mackensen A, Krause SW, Staib P, Schlegel F, Wätzig K, Rudolph R, Wattad M, Baur FK, Heit W, Beelen DW, Hüttmann A, Novotny J, Trenchel R, Lindemann A, Linck D, Jäger E, Al-Batran SE, Ottmann OG, Serve H, Reiber T, Semsek D, Waller C, Kühnemund A, Hoeffkes HG, Lambertz H, Schulz L, Tajrobehkar K, Mittermüller J, Rummel MJ, Burchardt A, Pralle H, Runde V, Kleiß M, Westheider J, Hoyer A, Tessen HW, Hesse A, Trümper L, Binder C, Schmidt CA, Hirt C, Sieber M, Eschenburg H, Wilhelm S, Depenbusch R, Rösel S, Eimermacher H, Spohn C, Moeller R, Schmitz N, Nickelsen M, Engel E, Haatanen T, Hollburg W, Platz D, Köster H, Bokemeyer C, Schafhausen P, Grote-Metke A, Bechtel B, Hemeier M, Sosada M, Ganser A, Schlegelberger B, Ho AD, Rohlfing S, Dengler J, Petersen V, Porowski P, Hahn L, Dietzfelbinger H, Gröschel W, Bartholomäus A, Pfreundschuh M, Kemmerling M, Hansen R, Reeb M, Link H, Mahlmann S, Mezger J, Schatz M, Schmier M, Gatter J, Neumann S, Heymanns J, Steinmetz HT, Schmitz S, Scheid C, Planker M, Frieling T, Lollert A, Neise M, Schröder M, Greif D, Kempf B, März W, Kremers S, Müller L, Hartmann F, Heil G, Goldmann B, Heinkele P, Gregor M, Theobald M, Fischer T, Thomas S, Hensel M, Plöger C, Schuster D, Brust J, Hieber U, Hehlmann R, Neubauer A, Burchert A, Graeven U, Lange C, Schmidt G, Völkl S, Schmidt B, Hitz H, Spiekermann K, Hiddemann W, Haferlach T, Haferlach C, Schnittger S, Stötzer O, Scheidegger C, Fischer C, Berdel WE, Koppele A, Hebart H, Snaga A, Schmidt P, Hoffmann R, Reschke D, Zirpel I, Sauer M, Lenk G, Eimermacher H, Theilmann L, Sandritter B, Schenk M, Dengler R, Herr W, Krause S, Braun B, Günther E, Wacker A, Pihusch R, Baldus M, Matzdorff A, Pollmeier G, Grimminger W, Hebart H, Geer T, Schanz S, Jürß C, Gassmann W, Seitz K, Kaesberger J, Mück R, Illerhaus G, Denzlinger C, Fiechtner H, Springer G, Hoffmann D, Jacki SH, Kanz L, Bross-Bach U, Döhner H, Stegelmann F, Kalhori N, Langer W, Nusch A, Weiß J, Kamp T, Schadeck-Gressel C, Schwerdtfeger R, Josten KM, Klein O, Fett W, Strotkötter H, Mainz C, Groschek M, Schlag R, Elsel W, Schüler F, Dölken G, Lindemann HW, Wolf HH, Schmoll HJ, Braumann D, Hoelzer P, Kleeberg U, Hossfeld D, Lange E, Schubert J, Weischer H, Dürk HA, Kirchner HH, Buß EC, Sievers B, Freier W, Kaiser U, Peest D, Römer E, Hermann T, Fauser A, Valverde ML, Menzel J, Kemper J, Hochhaus A, La Rosée P, Bentz M, Wilhelm S, Prümmer O, Kneba M, Strack U, Schoch R, Severin K, Stauch M, Karbach U, Vehling-Kaiser U, Köchling G, Weiß U, Middeke H, Neuhaus T, Martin H, Fetscher S, Schmielau J, Kämpfe D, Uppenkamp M, Weiß B, Thum P, Wuillemin W, Hofmann WK, Griesshammer M, Tischler HJ, Becker M, Hanfstein B, Müller M, Sauße S, Lunscken C, Kolb HJ, Lutz L, Hentrich M, Nerl C, Wendtner C, Berdel WE, Ladda E, Gnad M, Suna H, Schmidt E, Koschmieder S, Falge C, Wandt H, Wilhelm M, Köhne CH, Schweiger C, Müller-Naendrup C, Frühauf S, Ranft K, Theilmann L, Dencausse Y, Baake G, Ritter PR, Kloke O, Becker M, Göttler B, Völkl S, Schick HD, Weidenhöfer S, Weidinger P, Wacker D, Wehmeyer J, Kreuser ED, Schlenska-Lange A, Edinger R, Andreesen R, Wehmeier A, Stahlhut K, Käfer G, Cerny T, Hess U, Priebe-Richter C, Stange-Budumlu O, Demandt M, Freunek G, Heidemann E,

- Schleicher J, Mergenthaler HG, Boewer C, Zeller C, Laubenstein HP, Rendenbach B, Clemens M, Waladkhani AR, Forstbauer H, Müller F, Brettner S, Raghavachar A, Kunzmann V, Goebeler ME, Gmür J. Older patients with chronic myeloid leukemia ( $\geq 65$  years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV. *Ann Hematol.* 2014 Jul;93(7):1167-76.  
IF:.....
282. Schmeel C, Schmeel L, Coch C, **Schmidt-Wolf** IGH. Clinical trials on CIK cells: Update of the international registry on CIK cells (IRCC). *J Cancer Res Clin Oncol* 2015 May;141(5):839-49.  
IF: 3.1
283. Isaak A, Hauser S, Rogenhofer S, **Schmidt-Wolf** IGH. Matched pair analysis of dendritic cell versus targeted therapy in patients with advanced renal cell carcinoma. *Anticancer Res*, in Druck  
IF: 1.8
284. Schmeel et al. Flunarizine exhibits efficacy against lymphoma and myeloma cells. *Anticancer Res*, in Druck  
IF: 1.8
285. **Schmidt-Wolf** I. Kontinuierliche Therapie beim Multiplen Myelom bedeutsam. *Onkologie heute*. S. 33. 09/2014  
IF: 0.9
286. Christoph Sippel, Young Kim, Anja Wallau, Peter Brossart, Ingo **Schmidt-Wolf**, Peter Walger. AML versus ICU: Outcome of septic AML patients in an intensive care setting *Journal of Cancer Research and Clinical Oncology*, in Druck.  
IF: 3.1
287. Bullok KF, Sippel C, **Schmidt-Wolf** IGH. Increased effect of IMiDs by addition of cytokine-induced killer cells in multiple myeloma. *Hematological Oncology*, in Druck  
IF: 3.1
288. Y. Kim, I. **Schmidt-Wolf**. 20 Jahre Klinische Gentherapie in Deutschland. *DMW*, in Druck.  
IF: 0.5
289. Elias K. Mai<sup>1</sup>, Uta Bertsch<sup>1</sup>, Jan Duerig<sup>2</sup>, Christina Kunz<sup>3</sup>, Mathias Haenel<sup>4</sup>, Igor W. Blau<sup>5</sup>, Markus Munder<sup>6</sup>, Anna Jauch<sup>1</sup>, Baerbel Schurich<sup>7</sup>, Thomas Hielscher<sup>3</sup>, Maximilian Merz<sup>8</sup>, Barbara Huegle-Doerr<sup>1</sup>, Anja Seckinger<sup>1</sup>, Dirk Hose<sup>1</sup>, Jens Hillengass<sup>8</sup>, M.-S. Raab<sup>8</sup>, Kai Neben<sup>1</sup>, Hans-Walter Lindemann<sup>9</sup>, Matthias Zeis<sup>10</sup>, Christian Gerecke<sup>11</sup>, Ingo G. H. **Schmidt-Wolf**<sup>12</sup>, Katja Weisel<sup>13</sup>, Christof Scheid<sup>14</sup>, Hans Salwender<sup>15</sup> and Hartmut Goldschmidt<sup>1</sup>. Bortezomib/cyclophosphamide/dexamethasone (VCD) is equal regarding response rates and has a favorable toxicity profile compared to bortezomib/doxorubicin/dexamethasone (PAD) as induction therapy in newly diagnosed, transplant eligible myeloma patients: results from the multicenter, phase III clinical trial GMMG-MM5. *Leukemia*, in Druck  
IF: 10.4
290. Kim Y, **Schmidt-Wolf** IGH. Lenalidomide in multiple myeloma. *Expert Review of Anticancer Therapy*. In Druck.  
IF: 2.3
291. Bey, I (Bey, I.)<sup>[11]</sup>; Bergatt-Kuhl, B (Bergatt-Kuhl, B.)<sup>[11]</sup>; Arndt, S (Arndt, S.)<sup>[11]</sup>; Treppner, S (Treppner, S.)<sup>[11]</sup>; **Schmidt-Wolf, I (Schmidt-Wolf, I.)**<sup>[2]</sup>; Hallek, M (Hallek, M.)<sup>[11]</sup>; Wolf, J (Wolf, J.)<sup>[11]</sup>. 8 years patient navigators in the interdisciplinary tumor ambulance of CIO Köln Bonn - a role model for other cancer centers?! *ONCOLOGY RESEARCH AND TREATMENT, Volume: 37.*, 2014

IF: Not Available

292. Saußebe S, Krauß MP, Hehlmann R, Lauseker M, Proetel U, Kalmanti L, Hanfstein B, Fabarius A, Kraemer D, Berdel WE, Bentz M, Staib P, de Wit M, Wernli M, Zettl F, Hebart HF, Hahn M, Heymanns J, **Schmidt-Wolf** I, Schmitz N, Eckart MJ, Gassmann W, Bartholomäus A, Pezzutto A, Leibundgut EO, Heim D, Krause SW, Burchert A, Hofmann WK, Hasford J, Hochhaus A, Pffirmann M, Müller MC; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung and the German CML Study Group. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IV. *Blood*. 2015 Jul 2;126(1):42-9.  
IF: 10.5
293. Maximilian Merz<sup>1</sup>, Hans Salwender<sup>2</sup>, Mathias Haenel<sup>3</sup>, Elias K. Mai<sup>1</sup>, Uta Bertsch<sup>1,4</sup>, Christina Kunz<sup>5</sup>, Thomas Hielscher<sup>5</sup>, Igor W. Blau<sup>6</sup>, Christof Scheid<sup>7</sup>, Dirk Hose<sup>1</sup>, Anja Seckinger<sup>1</sup>, Jens Hillengass<sup>1</sup>, Marc S. Raab<sup>1</sup>, Baerbel Schurich<sup>1</sup>, Markus Munder<sup>8</sup>, Ingo G.H. **Schmidt-Wolf**<sup>9</sup>, Christian Gerecke<sup>10</sup>, Hans-Walter Lindemann<sup>11</sup>, Matthias Zeis<sup>12</sup>, Katja Weisel<sup>13</sup>, Jan Duerig<sup>14</sup>, Hartmut Goldschmidt<sup>1,4</sup>. Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: Interim analysis from the prospective GMMG-MM5 trial. *Haematologica*, in Druck.  
IF: 5.8
294. Kim Y, **Schmidt-Wolf** IGH. Multiples Myelom: Die Therapie ist im Fluss. Supplement: Perspektiven der Onkologie. *Dtsch Arztebl* 2015; 112(20): [27]; DOI: 10.3238/PersOnko.2015.05.15.08  
IF: 3.5
295. Stöhr E, Hänel M, **Schmidt-Wolf** IGH. Bendamustine in heavily pre-treated patients with relapsed or refractory multiple myeloma. *JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY*, <http://www.ncbi.nlm.nih.gov/pubmed/26156122>  
IF: 3.1
296. Mathias Witzens-Harig<sup>1</sup>, Axel Benner<sup>2</sup>, Jennifer Klemmer<sup>1</sup>, Elke Brants<sup>1</sup>, Michael Rieger<sup>3</sup>, Fabienne McClanahan<sup>4</sup>, Julia Brandt<sup>1</sup>, Julia Meissner<sup>1</sup>, Manfred Hensel<sup>5</sup>, Kai Neben<sup>6</sup>, Peter Dreger<sup>1</sup>, Eva Lengfelder<sup>7</sup>, Ingo **Schmidt-Wolf**<sup>8</sup>, Alwin Krämer<sup>1</sup> and Anthony D. Ho<sup>1</sup>. Rituximab Maintenance Therapy in Diffuse Large B-Cell Lymphoma. Results of the HD2002 prospective multicenter randomized Phase III trial. *Brit J Haematol*, in Druck  
IF: 5.0
297. Lauter B, **Schmidt-Wolf** IGH. Prevalence, supplementation and impact of vitamin D deficiency in multiple myeloma patients. *Cancer Invest*, in Druck  
IF: 2.2
298. Schmeel LC, Schmeel FC, Blaum-Feder S, **Schmidt-Wolf** IGH. In Vitro Efficacy of Naftifine Against Lymphoma and Multiple Myeloma. *Anticancer Res*. 2015 Nov;35(11):5921-6.  
IF: 1.8
299. Alois Gratwohl<sup>1\*</sup> MD, Markus Pffirmann<sup>2\*</sup> PhD, Axel Zander<sup>3</sup> MD, Nicolas Kröger<sup>3</sup> MD, Dietrich Beelen<sup>4</sup> MD, Jürgen Novotny<sup>4</sup> MD, Christoph Nerl<sup>5</sup> MD, Christof Scheid<sup>6</sup> MD, Karsten Spiekermann<sup>7</sup> MD, Jiri Mayer<sup>8</sup> MD, Herbert G Sayer<sup>9</sup> MD, Christiane Falge<sup>10</sup> MD, Donald Bunjes<sup>11</sup> MD, Hartmut Döhner<sup>11</sup> MD, Arnold Ganser<sup>12</sup> MD, Ingo **Schmidt-Wolf**<sup>13</sup> MD et al. LONG TERM OUTCOME OF PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA A Prospective Randomized Phase III Comparison of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) with Best Available Drug Treatment. *Leukemia* 2015 Oct 14. doi: 10.1038/leu.2015.281.  
IF: 10.4

300. Y. Kim, **Schmidt-Wolf** IGH. Neue Therapien beim Nieren-Ca. Pharma Fokus Onkologie 12: 38-41; 2015  
IF: 0

301. van den Berg H, Paulussen M, Le Teuff G, Judson I, Gelderblom H, Dirksen U, Brennan B, Whelan J, Ladenstein RL, Marec-Berard P, Kruseova J, Hjorth L, Kühne T, Brichard B, Wheatley K, Craft A, Juergens H, Gaspar N, Le Deley MC; Euro-EWING99 Group. Urban Ch, Meister B, Fink FM, Kerbl R, Stollinger O, Schmitt K, Ebetsberger G, Jones N, Ladenstein R, Gadner H, Maes P, Brichard B, Mazzeo F, Gil T, Dhooge C, Vermorken JB, Klein A, Kruseova J, Krarup-Hansen A, Nielsen O, Capra M, Pautard B, Rialland X, Maillart P, Plouvier E, Vérité C, Bui N'guyen B, Boutard P, Delcambre C, Bay JO, Demeocq F, Couillault G, Isambert N, Plantaz D, Desfachelles AS, Pigué C, Marec-Bérard P, Blay JY, Gentet JC, Duffaud F, Bertucci F, Sirvent N, Schmitt C, Rios M, Corradini N, Rolland F, Deville A, Thyss A, Michon J, Tabone MD, Pierga JY, Millot F, Munzer M, Edan C, Vannier JP, Guillemet C, Brun E, Berger C, Castex MP, Roche H, Lejars O, Linassier C, Oberlin O, Le Cesne A, Bauer S, Ebeling P, Flasshove M, Hartmann JT, Reichardt P, Mertens R, Osieka R, Gnekow A, Schlimok G, Henze G, Thuss-Patience P, Wickmann L, Reichardt P, Potenberg J, Reichardt P, Bode U, Schmidt-Wolf IG, Eberl W, Wolff T, Pekrun A, Hofmann A, Andler W, Schneider D, Lauterbach I, Zickler P, Göbel U, Borkhardt A, Sauerbrey A, Holter W, Bauer S, Ebeling P, Flasshove M, Eggert A, Klingebiel T, Niemeyer C, Heinz J, Reiter A, Rummel M, Runde V, Lakomek M, Trümper L, Beck J, Dölken G, Lindemann HW, Körholz D, Schmoll HJ, Schneppenheim R, Hossfeld DK, Bokemeyer C, Keles H, Welte K, Klein C, Kulozik A, Egerer G, Cyran J, Strumberg D, Freier W, Graf N, Pfreundschuh M, Gruhn B, Leipold A, Bentz M, Wehinger H, Schrappe M, Nolte H, Berthold F, Wolf J, Sternschulte W, Voelpel S, Frieling T, Moessner J, Selle D, Bucsky D, Bartels H, Mohren M, Fischer T, Kluba U, Gutjahr P, Dittrich M, Reiter S, Dürken M, Neubauer A, Beyer J, Christiansen H, Erdlenbruch B, Burdach S, Schmid I, Meyer zum Büschenfelde C, Peschel C, Oduncu F, Jürgens H, Berdel W, Held H, Hofmann-Wackersreuther G, Müller H, Peters O, Andreesen R, Krause S, Heits F, Geib-König R, Kasbohm M, Bürger D, Burghard R, Dickerhoff R, Bielack S, Feddersen I, Clemens MR, Handgretinger R, Hartmann JT, Debatin KM, Mayer-Steinacker R, Schoengen A, Schlegel P, Lee V, Chik KW, van den Berg H, Rodenhuis S, Gelderblom AJ, Hoogerbrugge P, Bökkerink JP, Pieters R, Corbett R, Österlundh G, Behrendtz M, Holmqvist BM, Hjorth L, Petersen C, Jakobson Å, Hjalmar U, Ljungman G, Angst R, Kühne T, Paulussen M, Leyvraz S, Rischewski J, Feldges A, Greiner J, Hess U, Exner GU, Niggli F, Knuth A, King D, McCarthy A, Henry P, Morland B, Rees H, Nicholson J, Traunecker H, Wallace H, Ronghe M, Simpson E, Cowie F, White J, Picton S, Lewis I, Leahy M, Stark D, Selby PJ, Heney D, Pizer B, McDowell H, Michalski A, Whelan J, Chisholm J, Pritchard-Jones K, Judson I, Brennan B, Hale J, Verrill M, Walker D, Sokal M, Wheeler K, Lee V, Gerrard M, Woll P, Lorigan P, Robinson M, Kohler J. Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: secondary analysis of the Euro-Ewing99-R1 trial. Eur J Cancer. 2015 Nov;51(16):2453-64. doi: 10.1016/j.ejca.2015.06.123. Epub 2015 Aug 10.  
IF: .....

302. Haaß W, Kleiner H, Weiß C, Haferlach C, Schlegelberger B, Müller MC, Hehlmann R, Hofmann WK, Fabarius A, Seifarth W; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung; German CML Study Group. Wernli M, Bargetzi M, Fischer von Weikersthal L, Gro V, Müller S, Hahn M, Schlimok G, Reichert D, Janssen J, Furkert J, Mandel T, Majunke PJ, Paliege R, Reichert P, Fuss H, Neben K, Staiger HJ, Heim D, Gratwohl A, Tichelli A, Korsten S, Henesser D, Le Coutre P, Arnold R, Ludwig WD, Ratei R, Teutsch C, Ludwig F, Urmersbach A, Blau I, Ihle H, Sperling C, Schelenz C, Koschuth

A, Kingreen D, Heßling J, Derwahl KM, Oldenkott B, Englisch HJ, Ludwig F, Thiel E, Burmeister T, Notter M, de Wit M, Rothaug W, Büschel G, Beyer J, Dahmen E, Biaggi C, Lämmle B, Friess D, Baerlocher G, Oppliger Leibundgut E, Tobler A, Just M, Schäfer E, Behringer D, Brandt M, Schmiegel W, Vaupel HA, Verbeek W, Ko YD, Weidenhöfer S, Sauerbruch T, Hahn-Ast C, Janzen V, Schmidt-Wolf I, Trenn G, van der Linde M, Pommerien W, Fritz L, Krauter J, Lordick F, Fritsch G, Pflüger KH, Diekmann C, Kullmer J, Doering G, Munzinger H, Hertenstein B, Peyn A, Mayer J, Záčková D, Kujickova J, Stier S, Wejda B, Möller-Faßbender F, Hänel M, Morgner A, Herbst R, Matek W, Lamberti C, Zöllner T, Koch B, Marth T, Henzel A, Wagner S, Woska E, Neumann F, Hoffknecht MM, Illmer T, Wolf T, Ehninger G, Kiani A, Platzbecker U, Aul C, Badrakhan CD, Giagounidis A, Flaßhove M, Henneke F, Moritz T, Simon M, Müller LL, Janz R, Eckart M, Häcker B, Rech D, Mackensen A, Krause SW, Staib P, Schlegel F, Wätzig K, Rudolph R, Wattad M, Baur FK, Heit W, Beelen DW, Hüttmann A, Novotny J, Trenscher R, Lindemann A, Linck D, Jäger E, Al-Batran SE, Ottmann OG, Serve H, Reiber T, Semsek D, Waller C, Kühnemund A, Hoeffkes HG, Lambert H, Schulz L, Tajrobehkar K, Mittermüller J, Rummel MJ, Burchardt A, Pralle H, Runde V, Klei M, Westheider J, Hoyer A, Tessen HW, Hesse A, Trümper L, Binder C, Schmidt CA, Hirt C, Sieber M, Eschenburg H, Wilhelm S, Depenbusch R, Rösel S, Eimermacher H, Spohn C, Moeller R, Schmitz N, Nickelsen M, Engel E, Haatanen T, Hollburg W, Platz D, Köster H, Bokemeyer C, Schafhausen P, Grote-Metke A, Bechtel B, Hemeier M, Sosada M, Ganser A, Schlegelberger B, Ho AD, Rohlfing S, Dengler J, Petersen V, Porowski P, Hahn L, Dietzfelbinger H, Gröschel W, Bartholomäus A, Pfreundschuh M, Kemmerling M, Hansen R, Reeb M, Link H, Mahlmann S, Mezger J, Schatz M, Schmier M, Gatter J, Neumann S, Heymanns J, Steinmetz HT, Schmitz S, Scheid C, Planker M, Frieling T, Lollert A, Neise M, Schröder M, Greif D, Kempf B, März W, Kremers S, Müller L, Hartmann F, Heil G, Goldmann B, Heinkele P, Gregor M, Theobald M, Fischer T, Thomas S, Hensel M, Plöger C, Schuster D, Brust J, Hieber U, Hehlmann R, Neubauer A, Burchert A, Graeven U, Lange C, Schmidt G, Völkl S, Schmidt B, Hitz H, Spiekermann K, Hiddemann W, Haferlach T, Haferlach C, Schnittger S, Stötzer O, Scheidegger C, Fischer C, Berdel WE, Koppele A, Hebart H, Snaga A, Schmidt P, Hoffmann R, Reschke D, Zirpel I, Sauer M, Lenk G, Eimermacher H, Theilmann L, Sandritter B, Schenk M, Dengler R, Herr W, Krause S, Braun B, Günther E, Wacker A, Pihusch R, Baldus M, Matzdorff A, Pollmeier G, Grimminger W, Hebart H, Geer T, Schanz S, Jür C, Gassmann W, Seitz K, Kaesberger J, Mück R, Illerhaus G, Denzlinger C, Fiechtner H, Springer G, Hoffmann D, Jacki SH, Kanz L, Bross-Bach U, Döhner H, Stegelmann F, Kalhori N, Langer W, Nusch A, Wei J, Kamp T, Schadeck-Gressel C, Schwerdtfeger R, Josten KM, Klein O, Fett W, Strotkötter H, Mainz C, Groschek M, Schlag R, Else W, Schüler F, Dölken G, Lindemann HW, Wolf HH, Schmoll HJ, Braumann D, Hoelzer P, Kleeberg U, Hossfeld D, Lange E, Schubert J, Weischer H, Dürk HA, Kirchner HH, Bu EC, Sievers B, Freier W, Kaiser U, Peest D, Römer E, Hermann T, Fauser A, Valverde ML, Menzel J, Kemper J, Hochhaus A, La Rosée P, Bentz M, Wilhelm S, Prümmer O, Kneba M, Strack U, Schoch R, Severin K, Stauch M, Karbach U, Vehling-Kaiser U, Köchling G, Wei U, Middeke H, Neuhaus T, Martin H, Fetscher S, Schmielau J, Kämpfe D, Uppenkamp M, Wei B, Thum P, Wuillemin W, Hofmann WK, Griesshammer M, Tischler HJ, Becker M, Hanfstein B, Müller M, Sauße S, Lunscken C, Kolb HJ, Lutz L, Hentrich M, Nerl C, Wendtner C, Berdel WE, Ladda E, Gnad M, Suna H, Schmidt E, Koschmieder S, Falge C, Wandt H, Wilhelm M, Köhne CH, Schweiger C, Müller-Naendrup C, Frühauf S, Ranft K, Theilmann L, Dencausse Y, Baake G, Ritter PR, Kloke O, Becker M, Göttler B, Völkl S, Schick HD, Weidenhöfer S, Weidinger P, Wacker D, Wehmeyer J, Kreuser ED, Schlenska-Lange A, Edinger R, Andreesen R, Wehmeier A, Stahlhut K, Käfer G, Cerny T, Hess U, Priebe-



Richter C, Stange-Budumlu O, Demandt M, Freunek G, Heidemann E, Schleicher J, Mergenthaler HG, Boewer C, Zeller C, Laubenstein HP, Rendenbach B, Clemens M, Waladkhani AR, Forstbauer H, Müller F, Brettner S, Raghavachar A, Kunzmann V, Goebeler ME, Gmür J. Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy. PLoS One. 2015 Jun 18;10(6):e0129648. doi: 10.1371/journal.pone.0129648. eCollection 2015.

IF:.....

303.R Rombo, Weiher H, **Schmidt-Wolf** IGH. Effect of chaetocin on renal cell carcinoma cells and cytokine-induced killer cells. In Druck, GMS 2016

IF: 0

304.Marc-Andrea Bärtsch<sup>1</sup>, Jana Schlenzka<sup>1</sup>, Elias Mai<sup>1</sup>, Maximilian Merz<sup>1</sup>, Jens Hillengaß<sup>1</sup>, Marc S. Raab<sup>1</sup>, Dirk Hose<sup>1</sup>, Anthony D Ho<sup>1</sup>, Anna Jauch<sup>2</sup>, Thomas Hielscher<sup>3</sup>, Christina Kunz<sup>3</sup>, Steffen Luntz<sup>4</sup>, Stefan Klein<sup>5</sup>, Ingo G. H. **Schmidt-Wolf**<sup>6</sup>, Martin Goerner<sup>7</sup>, Martin Schmidt-Hieber<sup>8</sup>, Peter Reimer<sup>9</sup>, Ullrich Graeven<sup>10</sup>, Roland Fenk<sup>11</sup>, Hans Salwender<sup>12</sup>, Christof Scheid<sup>13</sup>, Axel Nogai<sup>14</sup>, Mathias Haenel<sup>15</sup>, Hans W. Lindemann<sup>16</sup>, Hans Martin<sup>17</sup>, Richard Noppeney<sup>18</sup>, Katja Weisel<sup>19</sup>, Hartmut Goldschmidt<sup>1,20</sup>. Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma. BMC Cancer 16:290. DOI 10.1186/s12885-016-2321-2; 2016

IF: 3.4

305.Schmeel...clofibrate...Anticancer Res, in Druck

IF:.....

306.Nwangwu C, Weiher H, **Schmidt-Wolf** IGH. Increase of CIK cell efficacy by up-regulating cell surface MICA and inhibition of NKG2D ligand shedding in multiple myeloma.Hematological Oncol. In Druck

IF:.....

307.Esser L, Weiher H, **Schmidt-Wolf** IGH. Increased efficacy of SGN-35 and CIK cells towards CD30 positive lymphoma cell lines when being applied in combination. IJMS. <http://www.mdpi.com/1422-0067/17/7/1056/pdf>

IF 2.9

308.Schirmbeck N, Mey U, Olivieri A, Hensel M, Flieger D, **Schmidt-Wolf** IGH. DHAP in combination with rituximab versus DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B-cell lymphoma: a matched-pair analysis. Cancer Invest. <http://dx.doi.org/10.1080/07357907.2016.1212062> .

IF:.....

309.Ingo G.H. **Schmidt-Wolf**, Christoph Plass, John C. Byrd, Kathrin Frevel, Andreas Waha. Methylation of PTCH in chronic lymphocytic leukemia. In Druck, Anticancer Res

IF:.....

310.I. **Schmidt-Wolf**. Ergebnisse der FIRST-Studie. Onkologie heute. In Druck.

311.Corinna Jansen, Ingo **Schmidt-Wolf**, Ulrich Jaehde. Patientenindividuelles Nebenwirkungsmanagement bei intravenöser Tumortherapie. Onkologische Pharmazie, S. 16-20, Nr. 1/2016